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Abstract
Objective: To determine using amyloid Positron Emission Tomographic (PET) imaging,
whether amyloid burden indicated by Florbetaben (FBB) radiotracer, could predict cog-
nitive decline in the Parkinson’s disease individuals with Mild cognitive impairment
(PD-MCI).
Methods: In study, movement disorder society (MDS) criteria were used to classify
50 participant with PD-MCI. All subjects underwent clinical evaluation, Structural 3T
Magnetic resonance imaging and FBB PET imaging, along with cognitive assessments.
The PET images were assessed clinically and the Standard uptake value ratio (SUVRs)
were obtained for Region of interest (ROI) analysis, linear regression and multivariate
analysis to asses association with cognitive and clinical measure.
Results: At baseline, among the 50 scans, 22 % clinically FBB-positive. The Group-by-
Cognition showed an association between amyloid deposition in regions: neocortical,
frontal and temporal cortex, anterior and posterior cingulate, precuneus and putamen
with the global cognitive Z score, MoCa and Parkinson’s disease dementia "risk" score
(PDDRS). We also the pattern of amyloid accumulation in PD-MCI using multivari-
ate analysis ( principal Component analysis). We showed an association between our
principal components with the clinical classification of positivity and the neuropsy-
chological score. PCs showed worsening of cognitive impairment in the clinically FBB
positive group. In the context of FBB negative group there was no association with the
cognitive decline.
Conclusions: FBB-PET imaging allows in vivo visualization of amyloid deposition in
PD-MCI. At baseline measurements, our study show that amyloid accumulation could
potential contribute to cognitive deterioration in PD-MCI.
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Chapter 1
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second
most common neurodegenrative disorder after Alzheimer’s disease (AD)(Aarsland,
Brønnick, & Fladby, 2011). It is defined by the loss of neurons in the brain, specif-
ically the dopamine neurons in the substantia nigra par compacta which lies above
the brain stem (Samii, Nutt, & Ransom, 2004)(Braak et al., 2003). Dopamine is a neu-
rotransmitter that plays an important role in allowing normal movements (Braak et
al., 2003)(Aarsland et al., 2011). PD is traditionally defined by its motor symptoms,
which were initially defined by James Parkinson, and include resting tremors, rigidity,
bradykinesia, hypokinesia, akinesia and postural abnormalities (Thomas & Beal, 2007).
However, PD is also associated with non-motor related symptoms such as cognitive im-
pairment, dementia, mood disorder, psychosis, sleep disturbance, autonomic dysfunc-
tion and alterations in reward, motivation and mood (Chaudhuri, Tolosa, Schapira, &
Poewe, 2014). Historically, the survival rate of PD individuals was very low (due to
the motor symptoms); hence, the non-motor symptoms were not immediately appar-
ent. Over time, with improvements in treatment and general medical care, non-motor
features became more apparent, especially in elderly PD patients.
PD is expected to impose social and economic hindrance on society as the population
ages (Pringsheim, Jette, Frolkis, & Steeves, 2014). The prevalence of PD is about 160
per 100,000 and the incidence of PD is about 20 per 100,000 populations (Alves, Forsaa,
Pedersen, Gjerstad, & Larsen, 2008). In New Zealand and other developed countries,
PD affects about 1% of the population over 65 years of age (Aarsland et al., 2011)(de Lau
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& Breteler, 2006). It is more common in those over the age of 65 years. The demographic
trend projects that the current estimated prevalence of PD in New Zealand is 10,000
New Zealanders, will increase two-fold by 2035 and four-fold by 2050 (Bach, Ziegler,
Deuschl, Dodel, & Doblhammer-Reiter, 2011). PD prevalence varies across-cultures
due to difference in environmental exposure and genetic factors. Studies have shown
prevalence of PD is higher in males than in females and is also associated with the
aging process (Alves et al., 2008)(Pringsheim et al., 2014). More importantly, PD can
reduce life expectancy and lead to significant disability and impaired quality of life.
Dementia is 1.7 – 5.9 times more likely in PD patients than in healthy individuals
(Factor & Weiner, 2007). The cumulative prevalence of dementia in PD is approxi-
mately 75-90 % (Aarsland & Kurz, 2010). Dementia develops due to the progression
of degeneration and the deposition of Lewy bodies in the cerebral cortex and limbic
structures (Madhavi, 2014). Many demographic and clinical features have been associ-
ated with dementia in Parkinson’s patients such as older age and motor impairment.
These features are Parkinsonism, age, mild cognitive impairment (MCI), neuropsychi-
atric symptoms and genetic factors. However, studies have been unable to predict the
onset of dementia after PD diagnosis, since it is highly variable and can occur anywhere
from 2-20 years (Aarsland & Kurz, 2010). After diagnosis, this variability provides a
therapeutic window. The ability to identify patients with a higher risk of developing
dementia will lead to more effective treatment choice, timing and development.
β-Amyloid is most commonly known as a pathological hallmark for AD (discussed in
detail in section 1.1.4) (Gertz & Rajkumar, 2010). However, it has now been recognized
as a significant contributor to cognitive impairment in PD. Amyloid deposition in AD
is a robust finding and predictive of individuals that will go on to developing dementia.
This shows that quantification of the amyloid plaque burden may play a critical role
in predicting which individuals are at a ’higher risk’ of developing dementia and this
could eventually help in the treatment and disease management of PD. Neuroimaging
with Positron Emission Tomography (PET) and advanced Magnetic Resonance Imag-
ing (MRI) has shown to be a useful biomarker for providing pathological information in
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cases of AD. Recent studies have demonstrated the importance and usefulness of amy-
loid PET imaging as a tool for diagnosis and understanding the progression of MCI in
AD and PD (Gomperts, Locascio, & Rentz, 2013). The first PET ligand to be used as a
biomarker for amyloid-beta in AD was 11C-Pittsburgh Compound B (PIB) (Potecorvo
& Mintun, 2011). Along with PIB, many other studies have looked at other radiophar-
maceuticals as a potential amyloid label, such as Florine-18 radiotracers (Potecorvo &
Mintun, 2011). In AD these radiotracers have been a useful tool in diagnosing the early
stages of disease in patients that are cognitively normal or have mild cognitive im-
pairment. Clinical trials of anti-amyloid therapeutic intervention are ongoing therefore
adequate quantification and location of β-amyloid is essential.
This thesis, will investigate the potential of FBB-PET imaging in PD-MCI subject in or-
der to identify individuals with a higher risk of developing dementia in the near future.
In order to do so, it will look at amyloid burden in PD-MCI patients using the FBB-PET
imaging. It will further look at understanding the pathophysiology of cognitive de-
cline and dementia. In particular look at how amyloid burden effects the progression
of cognitive decline. It determining the association of amyloid accumulation with the
cognitive decline in PD-MCI subjects.
The thesis is composed of five chapters, each of them dealing with different aspects of
this study.
Chapter 1 introduces and defines basic terminology and reviews literature useful in the
context for this thesis. It is subdivided into three parts. Part one describes Parkinson’s
disease and explains the pathology and problems associated with the disease. Part two
describes the neuroimaging used in imaging amyloid deposition in neurodegenrative
disorders and it explains the basic concepts of these imaging techniques and discusses
previous literature on amyloid imaging using these techniques. Chapter 2 describes
and justifies the study design and data gathering method used. It also outlines the
method of analyses used i this study. Chapter 3 addresses the results from the data
analysis. Chapter 4 discusses the results we acquired, limitations and future work.
Chapter 5 summaries the findings of this thesis.
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1.1 Parkinson’s Disease
1.1.1 Cognitive Impairment in Parkinson’s Disease
Cognition is defined as the brain’s ability to acquire knowledge and understand through
thought, experience and the senses. This unique ability of the brain is affected by many
factors such as normal aging and mental health. However, it is severely affected in indi-
viduals who are suffering from a neurodegenerative disorder. The degree of cognitive
impairment ranges from being mild (mild cognitive impairment) to highly severe (de-
mentia) and varies with the progression of disease generally worsening as the disease
progresses (Yarnall, Rochester, & Burn, 2013). At the onset of the disease even non-
demented patients are found to have some degree of cognitive impairment (Yarnall et
al., 2013). Many studies have shown that the global disability level between PD-normal
cognition (PD-N), PD-mild cognitive impairment (PD-MCI) and PD Dementia (PDD)
increases in a step-wise manner (Yarnall et al., 2013).
Following the Movement Disorder Task Force Criteria, cognition is divided into five
domains (Litvan, Goldman, I.Troster, et al., 2012). The five cognitive domains that
could potentially be affected are: learning and memory (ability to learn, remember
and acquire new information), attention and speed of processing (ability to focus and
understand the task at hand in a timely manner), executive function (problem solv-
ing, planning and performing), visuospatial functions (manipulate and understand
non-verbal information) and language (ability to understand, use and manipulate lan-
guage) (Fernandez, Crucian, Okun, Price, & Bowers, 2005a)
Cognitive impairment is one of the defining features of AD. However, it is now also
seen as a major issue in other neurodegenerative disorders including PD. In the past 30
years, studies have analysed and investigated in detail the epidemiology of cognitive
decline and dementia in PD. It is clear that cognitive deterioration is a common, pro-
gressive and disabling factor in PD. Although the majority of PD patients are affected
by cognitive decline, the specific deficits can vary between individuals.
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1.1.2 Mild Cognitive Impairment
Mild Cognitive Impairment (MCI) was initially seen as a symptom of AD. However,
it is now well-established that individuals with PD also exhibit PD-MCI prior to the
development of dementia and that cognitive decline is also one of the main symp-
toms of PD. The frequency of MCI in PD ranges anywhere from 21-62%, with an av-
erage prevalence of around 15-18 % for individuals aged 70 years (Goldman & Litvan,
2011)(Madhavi, 2014).
PD-MCI is now recognized as an appropriate stage to address the underlying pathogenic
process leading to dementia. It is known as the intermediate stage of impairment from
normal cognition to dementia; defined as two impairments at -1.5 standard deviation
below the normative data in any of the five task force cognitive domains (discussed
in detail in section 2.2) (Palavra, Naismith, & Lewis, 2013) (Dalrymple-Alford et al.,
2011a). In PD-MCI, daily life activities are generally unaffected or are only slightly
affected. Neuropathology of PD-MCI is heterogeneous, showing deposition of neocor-
tical Lewy bodies, cortical amyloid, Tau, tissue loss and neurotransmitter dysfunction
(Compta et al., 2011) (Jellinger, 2010a).
PD-MCI is diagnosed on the basis of neuropsychological testing. These neuropsycho-
logical batteries asses individuals and allocate them into certain groups: PD-N, PD-
MCI and PDD. For example Litvan et.al., Diagnosis criteria for MCI in PD; movement
disorder society task force guidelines, allow characterization of the clinical syndrome
and diagnostic methods (Litvan, Goldman, I.Troster, et al., 2012). It is designed using
the MDS task force criteria addressing the specific issue of PD. It is divided into four cri-
teria for the diagnosis of PD-MCI: Inclusion criteria, Exclusion criteria, Specific guide-
lines for PD-MCI level 1 and level 11 categories and Subtype classification for PD-MCI.
The inclusion criteria is an initial diagnosis for PD using the UK PD brain bank criteria
and PD-MCI is characterized as an informative decline in cognition abilities. The ex-
clusion criteria is used to assess for PDD using the MDS task force (Dalrymple-Alford
et al., 2011b). The specific guidelines for PD-MCI level 1 and level 2 are the abbreviated
assessment and comprehensive assessment respectively, for the specific diagnosis for
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PD-MCI. Lastly, the subtype classification for PD-MCI is important in exploring the im-
pairments in specific cognitive domains. It also classifies PD-MCI into two categories :
single and multiple domain. The single domain is defined by the presence of two ab-
normal test in a single cognitive domain with other domains unimpaired. The multiple
domain is defined as one abnormal test in at least two or more cognitive domains. Even
with the criteria and guidelines for diagnosis of MCI, it is still challenging because it
can not be generalized to all patients, since an individual’s mental level of function-
ing can have a huge influence on their performance on neuropsychological measures
(Litvan, Goldman, I.Troster, et al., 2012).
1.1.3 Dementia
Dementia is defined as a syndrome resulting in multiple-domain cognitive impairment
severe enough to impair daily life (Quinn, 2014). The general difference between de-
mentia and MCI is the impact of the syndrome on an individual’s daily functioning.
Dementia has a significant effect on an individual’s everyday functions (Fernandez et
al., 2005a). It was first introduced by Alois Alzheimer, while describing what came
to be known as AD. According to the epidemiological reports since 2010, about 35.7
million people worldwide have been affected by dementia (Quinn, 2014). For many
years, AD has been seen as the main cause of dementia. However, many other neuro-
logical disorders and medical conditions can lead to dementia over time, for example
PD, Lewy Body disease, vascular insult, human immunodeficiency virus, Huntington’s
disease, Pick disease, depression, hypothyroidism and vitamin B12 deficiency (Quinn,
2014) (Mendez & Cummings, 2003).
In PD, recent studies have shown that the cumulative prevalence of dementia is around
75-90% (MA.Hely, Reid, Adena, Halliday, & Morris, 2008). The incidence of dementia
is fourfold higher in PD cases in comparison to the general normal aging population.
The effects of dementia on individual daily activities have a huge impact on the quality
of life of an individual, public health services and cost of care. The pathological associ-
ation of dementia in PD is classified into three main categories : subcortical pathology,
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limbic or cortical Lewy bodies type degeneration and AD type pathology (Emre, 2003)
(Quinn, 2014).
Recently, much effort has been placed on diagnosis criteria designed to distinguish dif-
ferent types of dementia (Emre et al., 2013). Clinical diagnostic criteria used for PDD
is similar to PD-MCI. However, in the case of dementia there must be impairment in
2 cognitive domains, along with decline in an individual’s everyday activities not in-
cluding the motor impairments (Dalrymple-Alford et al., 2011b) (Fernandez, Crucian,
Okun, Price, & Bowers, 2005b). Many individuals with PD-MCI will develop PDD,
but the time of dementia onset varies wildly from patient to patient, ranging anywhere
from 2-20 years after diagnosis. Previous longitudinal studies investigating the conver-
sion of PD-MCI transition to dementia have found that about 62% of PD-MCI patients
converted to dementia in comparison to 20% of PD patient with normal cognition (PD-
N) (Palavra et al., 2013). Therefore, it is important to understand PD-MCI and the
pathology driving transition to dementia. This could provide greater prognostic accu-
racy and more targeted intervention.
1.1.4 Amyloid
Amyloid accumulation has been associated with pathology of many neurodegenera-
tive disorders such as AD, PD, Lewy body disease and Huntington’s disease. In PD,
amyloid accumulation is a likely contributor to development of Dementia.
β-Amyloid is generated from sequential amyloid precursor protein (APP) proteolysis.
APP is a type 1 transmembrane glycoprotein, present at high levels in the brain. It
belongs to a family of amyloid precursor-like proteins (APLP-1 and APLP-2). The fun-
damental role of APP is unknown and is a topic of intense research (Pearson & Peers,
2006). Many studies suggest that APP poses neurotropic properties. The high level of
APP plays an important role in neuronal growth, cellular survival and neuronal migra-
tion, shown by Oh et al. who looked at the effect of wild-type APP in transgenic mice
and found enlargement of neurons and epitomized effects in these mice. Additionally,
in a recent study, Young-Pearse et al. demonstrated that APP favors cognitive function
and synaptic density improvement (del C. Cárdenas-Aguayo et al., 2014).
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In APP processing, there is two pathways. In the non-amyloidogenic pathway, solu-
ble extracellular fragments sAPP- α, are released by cleavage of APP by α -secretase.
In the presence of γ-secretase at the plasma membrane, sAPP- α is further cleaved
to form APP intracellular C-terminal domains. The second pathway is the amyloido-
genic pathway in which the N-Terminal soluble extracellular fragments, sAPP- β and
CT99 are released by cleavage of APP by β -secretase. These fragments are further
cleaved by γ-secretase to form amyloid-beta (Aβ) fragments (as shown in figure 1.1)
(del C. Cárdenas-Aguayo et al., 2014)(Selkoe, 2004) (Vallabhajosula, 2011). The Aβ
fragments aggregate to form the amyloid-beta plaque that accumulates in the brain
during neurodegeneration.
FIGURE 1.1: Schematic diagram of β-Amyloid peptide formation from
cleavage of APP by β- secretase and γ-secretase. (Vallabhajosula, 2011)
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In the healthy brain, amyloid-beta aggregates are presented in low levels during synap-
tic activity. Studies have shown the capability of amyloid-beta to function as a chelator
and antioxidant when presented at low levels (del C. Cárdenas-Aguayo et al., 2014),
with the ability to capture redox metals such as Cu, Fe and Zn. Furthermore, low phys-
iological levels of Aβ favours learning and memory processes and regulates synaptic
plasticity (del C. Cárdenas-Aguayo et al., 2014). However, mutation in APP can lead to
enhanced levels of generation of the Aβ aggregates which have been linked to neurode-
generative disorders, neurotoxicity and cell death. In the case of PD, amyloid plaque
accumulation is linked to potential decline in cognitive function and ultimately to PDD
pathology. Studies have demonstrated the contribution of accumulation of β-Amyloid
in the progression of cognitive decline in individuals with PD and other neurodegen-
rative disorders (Gomperts et al., 2013). It has been shown that 50% of PDD patients
undergo secondary diagnosis of AD. Neuroimaging of β-Amyloid in case of AD has
shown to be a useful tool in providing pathological information. However, in the case
of PD and PDD, previous imaging data has generally shown no difference. Few studies,
in previous years have shown association between amyloid deposition and cognition
or future dementia in PD (Gomperts et al., 2013). We want to see whether β-Amyloid
deposition adds an additional ’hit’ to PD-MCI, which pushes them to convert to PDD.
We also want ti investigate whether we can see an association between β-amyloid and
cognition in PD.
1.2 Medical Imaging
1.2.1 Positron Emission Tomography (PET)
Fundamental Principles of operation
Positron emission was first discovered in 1933 by Thibaud and Joliot. The objective
of PET scanning is to measure the concentration of distribution of radionuclide in the
living body. The radionuclides used in PET imaging have one principle property beta
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plus (positron) decay . It is this positron decay that is employed in PET imaging in or-
der to acquire PET images. The most common positron-emitting isotopes used in PET
imaging are carbon-11, Oxygen-15, Nitrogen-13 and Fluorine-18 (Ziegler, 2005). These
isotopes are produced using a Cyclotron (charged particle accelerator) (Bushberg, Seib-
ert, Leidholdt, & Boone, 2002). It bombards stable nuclei with high energy to generate
radioactive isotopes. These isotopes have two things in common. Firstly, their nuclei
are rich in protons which means that in order to stabilize themselves, they convert the
excess proton into a neutron and release a positron and neutrino. Secondly, they have
relatively short half-lives, enabling an adequate trade-off between image quality and
minimal radiation dose. These isotopes are distributed in the subject with the help of
carrier molecules (biological substrate). The biological substrate used and tagged to the
isotope depends on there specific function in the body. The most common biological
substrates used in PET imaging are glucose, H2O, CO2 and O2 (E.Schmitz, Alessio, &
Kinaham, 2003). The isotopes are tagged to a specific carrier molecule chemically to
create a specific radionuclide that will bind to a specific target (Bushberg et al., 2002).
These radionuclides are then injected into the bloodstream and undergo positron decay.
During positron decay of the radionuclide, a proton converts into a neutron, resulting
in the release of a positron with specific kinetic energy Q, as shown in equation 1.1
(Basu, Kwee, Surti, Akin, & Yoo, 2011).
ZAX→ Z − 1AY + β + ν +Q (1.1)
A positron is an antimatter equivalent of an electron and it annihilates with an elec-
tron. So when a positron is released, it travels a certain distance and then annihilates
with a nearby electron, losing its kinetic energy (Basu et al., 2011). The range that the
positron travels depends on the positron’s energy and the characteristics of the tissue
(density and the atomic number). The annihilation leads to the conversion of electron
and positron into collinear emission of two 511 KeV photons (Bushberg et al., 2002).
Due to the collinear emission of the photons, the photons emitted travel in opposite
directions to one another in a straight line (known as the Line of Response (LOR)),
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shown in figure 1.3. The emission of two photons ensures the conservation of linear
momentum and energy (Basu et al., 2011).
FIGURE 1.2: General principle of PET imaging : Release of positron,
annihilation with electron and production of two 511 KeV annihilation
photons.(Phelps, 2006)
The two annihilated photons in the opposite direction are detected simultaneously by
the detectors surrounding the patient, allowing localization of the origin of these pho-
tons. This mechanism is known as the annihilation coincidence detection. The detec-
tors are arranged in an array surrounding the patient in a circular fashion (Bushberg
et al., 2002) (Basu et al., 2011). There are three possible annihilation coincidence event
types detected by PET detectors. These events are: true coincidence (two photons from
a single annihilation event are recorded within a specific coincidence time window of
6 - 15 nanosecond (Cherry, Sorenson, & Phelps, 2003)), Accidental coincidence (ran-
dom coincidence-two single photons from two unrelated annihilation events reach the
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detector in the coincidence time window and the event is registered as a single coinci-
dence event) and Scattered coincidence (event due to Compton scattering in the patient
body).
Both the scattering and accidental coincidence detection lead to incorrect LOR and re-
sults in incorrect positional information, loss of contrast, hazy background and noise
in the PET image. These coincidences are the main source of inaccuracy in clinical
PET scanning and so correction for these is important, to acquire fine detail and useful
information from PET scans(Cherry et al., 2003).
Data Acquisition and image formation in PET imaging
Photon detection and scintillator detector
For coincidence detection, the detectors in the PET scanner are arranged in a circular
fashion. They are made up of a scintillator crystal such as sodium iodide doped with
thallium (NaI (TI)) and bismuth germinate (BGO), Lutetium oxyorthisilicate (LSO),
coupled with a photomultiplier tube (PMT) in a block design (Cherry et al., 2003). A
matrix of scintillator crystals is attached to 4 PMTs arranged in 2X2 matrix. The matrix
is achieved by segmenting the crystal into smaller elements. The block detector allows
the small scintillator crystal to be used to improve spatial resolution while keeping the
number of PMT as low as possible to control the cost. The scintillator crystal uses the
concept of light distribution and centroid calculation in four PMT to identify in which
element the gamma ray was detected from. The choice of scintillator used in the de-
tector depends on the stopping power of the detector for 511KeV photon, the effective
atomic number of the scintillator crystal, the scintillator decay time, the light output
per KeV of photon energy, and the energy resolution of the detector (E.Schmitz et al.,
2003). These parameters are important as they determine the spatial, energy and timing
resolution of the system and the efficiency of the detector in detecting true coincidences
(Farncombe & Iniewski, 2013).
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FIGURE 1.3: Scheme of a Scintillator Block Detector. Fundamental prin-
ciple of scintillator block detector.(Phelps, 2006)
In principle, the scintillator crystal interacts with the gamma rays and the energy from
the gamma rays is converted to light. 511 KeV annihilation photons create tens of
thousands of visible wavelength photons in the scintillation process. The light energy
from the crystal is passed on to the PMT, which produces pulses of electrical signal. A
PMT tube is a vacuum glass tube which consists of a photocathode that converts the
light energy into photoelectrons, which are then passed on to dynodes. The dynodes
multiply the photoelectrons depending on the voltage difference between the dynodes
and the photocathode. The amplified photoelectrons are passed onto the anode which
in turn convert the photoelectrons into an electrical pulse signal (Casey & Nutt, 2007).
Data processing and correction
One of the most important techniques performed to correct and eliminate detection of
unwanted coincidences, and also determine the origin of true coincidence is Time of
Flight (TOF). Time of Flight is applied to improve the single to noise ratio (SNR) in the
image and also helps reduce the random coincidence detection (Basu et al., 2011). The
concept of Time of Flight (TOF) in PET image reconstruction is based on measuring the
precise time that each of the coincident photons are detected at, for each of the anni-
hilation coincidence events. The majority of PET scanners acquire coincidence event
pairs which lie in the time window of 6-15 nanoseconds (Cherry et al., 2003). However,
these scanner do not record the time of arrival of these photons. As mentioned earlier,
14 Chapter 1. Introduction
a scattering coincidence can be detected if it lies between this time window. This could
result in the wrong location of the coincidence event and leads to noise in the recon-
structed image. To acquire images with Time of Flight correction, the detector must
have a short light decay times which is accomplished by using LSO or LYSO scintilla-
tor crystals (Basu et al., 2011). In the TOF technique, the arrival time of every event is
recorded . If the event is detected between the time window of 0.5 nanoseconds then
the time difference ∆τ is calculated and computed (Cherry et al., 2003) (Farncombe
& Iniewski, 2013). Using the time difference, the location of the annihilation event is
calculated (equation 1.2).
d =
∆τc
2
(1.2)
Where d is the location of annihilation event and with the center of the gantry as the
midpoint, c is the velocity of the light (3 x 10-9 cm/sec). To acquire information about
the events and the image, the probability of line of response (LOR) is recorded, which
represents the location of the annihilation event. This allows the LOR to be shorter than
the LOR from detector to detector. Due to the shorter time window of 0.5 nanoseconds,
the detection of random and scattered coincidences is minimized (Rich & Christian,
2013).
Once all the lines of coincidence are observed and recorded by the detector as shown
in figure 1.4, they are organized in a sinogram (raw data format). In the sinogram,
each sinusoidal curve represents all the lines of coincidence passing through a single
point in the subject. The sinogram is further modified to acquire only information in the
form of true coincidence events and eliminates attenuated information and information
obtained by the scattered and random coincidence events (E.Schmitz et al., 2003).
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FIGURE 1.4: Schematic representation of the Image Acquisition and Re-
construction in CT/PET imaging System. (Striet, 2010)
Another important correction done in PET imaging is attenuation correction (Kinahan,
Hasegawa, & Beyer, 2003). The emission of radiation from the radionuclide inside the
body is not always observed by the detector due to two factors: absorption of radiation
within the body and the scattering of photons away from the detector. This loss of
detection of true coincidence is known as attenuation. In PET brain imaging, half of
the true coincidence is lost due to attenuation.
In PET imaging, attenuation of photons is characterized by the linear attenuation co-
efficient (µ). The linear attenuation coefficient is the transmission probability of the
photon through any material. Attenuation depends upon the thickness of the body,
atomic number and density (Ay & Sarkar, 2003). It can affect the visual quality of the
PET images (image noise, image artifacts and image distortion) and in turn affect the
quantitative information of PET data (Ay & Sarkar, 2003). The probability of the the co-
incidence acquired by the detector depends on the linear attenuation coefficient of the
tissue at 511 KeV and the total length of intersection within the body (T), as illustrated
below in equation (1.3).
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P (det) = e−µT (1.3)
Where P(det) is the probability of detection (Cherry et al., 2003).
The probability of detection is independent of the location of the source, and only de-
pends on the length of the LOR. Attenuation correction is performed by generating
attenuation maps, which represent the spatial distribution of the linear attenuation co-
efficient of 511 KeV photon. There are two ways the attenuation map can be gener-
ated in PET imaging: by the transmission method and the transmission-based method
(E.Schmitz et al., 2003).
In clinical application, the most common and effective method used is the transmission-
based method. In transmission-based method, an external source is used, such as a CT
scan. In our study, we have used this CT-based attenuation correction method in ac-
quiring PET images corrected for attenuation. Here CT information is used to generate
attenuation maps (E.Schmitz et al., 2003). A tomographic reconstruction algorithm is
used to calculate the attenuation coefficient at the applied voltage energy. The attenu-
ation coefficient is further converted to an attenuation coefficient at 511 KeV energy, to
allow correction for the 511 KeV photon emission in the PET scan. Using CT-based at-
tenuation correction allows higher photon fluence rates, faster transmission scan along
with a true anatomical structural image and true capability of locating the radionuclide,
which is not achieved in a normal transmission scan (E.Schmitz et al., 2003).
Applying the CT image to the PET image also overcomes a limitation of PET imaging
namely, the lack of an anatomical reference frame; thereby providing the specificity of
the examination in neuroimaging. For example, in most clinical cases, the PET (func-
tional) image will be co-registered to the CT (structural) image (E.Schmitz et al., 2003).
Clinical PET scanners now routinely use the Iterative Reconstruction method (Iniewski,
2009). This reconstruction method, along with attenuation correction, allows for three
dimensional image representing the distribution of the radionuclide in the body. Itera-
tive reconstruction methods solve the system of linear equations to acquire projection
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data from an initial image, by converting the image into pixels or voxels (volume el-
ements or pixels) (Iniewski, 2009) (Cherry et al., 2003). It relates the image pixel and
projections using a linear equation system which can be represented as below:
P = AX (1.4)
where P is the array of projections, X is array of image pixels and A is the coefficient
matrix of the system. The matrix A, consists of the weighted factor contribution from
the image pixel to the projections (Zeng, 2010).
Iterative Reconstruction initially estimates a uniform distribution of activity (image).
Using forward projection, it sums all the intensities in the projection data of the esti-
mated image. The summed estimated projection data is then compared with the actu-
ally recorded projection data, in order to acquire a close approximation to the recorded
projection data. This is achieved by finding the difference between the estimated and
the recorded projection data and back projecting the error projection on to the esti-
mated image. This process is repeated until the difference between the actual data and
the projected data is minimized as shown in figure 1.5. Lastly, the images are smoothed
to eliminate noise (Iniewski, 2009) (Cherry et al., 2003).
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FIGURE 1.5: Basic schematic representation of principle of Iterative Re-
construction Algorithm (Iniewski, 2009)
The high sensitivity, specificity and accuracy of these reconstructed images make PET
images a useful tool for the clinical diagnosis of certain disease. Due to this unique
quality of PET imaging, it makes it an ideal tool to employ to understand amyloid
accumulation in PD-MCI.
In order to evaluate the PET images, abnormal tissue radiotracer uptake relative to the
normal tissue is determined (Standard Uptake Value Ratio). Standard Uptake Value
Ratio (SUVR) is a method of acquiring the concentration of radioactivity in the PET
imaging. It is sometime referred to a the differential uptake ratio (DUR). In this thesis
we will refer to it as SUVR. It is obtained by measuring the concentration of radioactiv-
ity in the region of interest on a PET image, normalised for the injected dose and body
weight of an individual (Saha, 2015).
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Amyloid PET Imaging
Amyloid has been a hot topic in neurological research for the past ten years, particu-
larly in AD. The development of in-vivo amyloid PET imaging has provided a break-
through in clinical neuroscience. The amount of amyloid accumulation can now be
measured before autopsy. In AD, Amyloid PET imaging has been used to show in-
crease deposition relative to healthy aging, and is one of the most robust findings.
Presence of amyloid is even predictive of future development of dementia in those
with MCI (Gomperts et al., 2013). It has been used in PD studies to evaluate the as-
sociation of amyloid aggregation with PD symptoms and its pathology in PD. Many
studies using amyloid imaging have shown amyloid accumulation in PD with signif-
icant spatial distribution in comparison to AD (Campbell et al., 2013). Pathological
studies, say that up to 50% of PDD cases have amyloid accumulation that results in a
secondary diagnosis of AD (at autopsy) (Jellinger, 2010b) (Compta et al., 2011). In the
field of PD, one of the interesting questions many researchers are interested in is the
story of amyloid in PD and how it is associated with cognition in PD (Gomperts et al.,
2013).
The first attempt at imaging amyloid in-vivo was performed by Friedland and col-
leagues (Friedland et al., 1997). They used the radiotracer technetium-99 linked to an
amyloid antibody fragment in AD patients using single-photon emission tomography
(SPECT). This was an unsuccessful attempt since the fragment was unable to effec-
tively cross the blood brain barrier (Friedland et al., 1997). However, it started the
interest in developing and investigating the potential of amyloid binding radiotracers
which will efficiently allow amyloid imaging. Since then, the possibility of imaging
amyloid has increased due to the development of specific tracers for PET that bind
efficiently to amyloid plaques (Potecorvo & Mintun, 2011). The tracers belong to a va-
riety of chemical classes such as thioflavin T, stilbenes, benzoxazoles and benzofurans.
These tracers are 18-fluoro-labelled 1,1 dicyano-2-[6-(dimethylamino)-2-naphthalenyl]
propene (FDDNP), 11 C-labelled [N-methyl]-2-[4- methylaminophenyl-6 hydroxyben-
zothiazole](Pittsburgh Compound-B, PIB), 18F-florbetapir ((E)-4-2(6(2(2(2[18F] fluoroethoxy)
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ethoxy) ethoxy) pyridin-3-yl) vinyl)-N-methylbenzenamine) and 18F-florbetaben [trans-
4-(N-methyl-amino)-4 (2(2(2[18-F]fluoro-ethoxy) ethoxy) ethoxy) stilbene](FBB) and many
more (Richards & Sabbagh, 2014).
Florbetaben (FBB) is one of a handful of new 18-F-Labeled tracers produce for β-Amyloid
imaging in humans. It is synthesized in a similar fashion to other F-18 tracers. A non-
radioactive precursor is labelled to 18-F, which undergoes acid hydrolysis and chro-
matography for purification. In terms of toxicity, FBB is found to be under the tolerance
limit with no mutagenic properties. It was demonstrated that a quantitative measure-
ment and a visual interpretation can be made with a 20min PET scan, following a 90
minutes post-injection period (Richards & Sabbagh, 2014).
Preclinical and post-mortem AD studies have shown that the binding affinity and den-
sity of FBB to Aβ aggregates is in the range required for bioimaging. On average, the
binding affinity for Fluorine-18 tracers is around 6.7 nM and does not show any bind-
ing to Lewy bodies, Pick bodies or glial cytoplasmic inclusions (Richards & Sabbagh,
2014). As a diagnosis tool for early AD, it has been proven to be cost effective and pro-
vides improved quality of life to the patient. This finding was provided by Guo and
colleagues, who investigated the impact of FBB on diagnostic confidence and economic
implications (Guo et al., 2012). They designed a model which allowed exploratory
analysis using payer and society perspectives, along with the course of disease and the
time of diagnosis. They showed that using FBB PET as a diagnosis tool in AD improves
quality of life for a patient by providing faster diagnosis compared to other diagnosis
tools and has a positive impact on economic output (Guo et al., 2012).
PIB was the first amyloid PET tracer and is the most studied amyloid-binding radio-
tracer. It was first used in 2003 in AD mice models to show amyloid deposition as a
hallmark of AD. It showed rapid entry in the brain and efficient binding to amyloid
aggregates; specifically to extracellular and intravascular fibrillar amyloid-beta deposi-
tion, without binding to neurofibrillary tangles or Lewy bodies. Correlations between
PIB and amyloid aggregates have been well documented in AD cases. AD PET studies
have shown association between PIB binding and the cognitive decline, in the early
stages of AD. Edison and colleagues showed that uptake of C-11 PIB in AD revealed
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an increase in β-amyloid in the areas associated with cognition deterioration (cingulate,
frontal, temporal, parietal and occipital cortical area) (Gomperts et al., 2013). Another
C-11-PIB PET study associated with amyloid deposition in AD reported a two-fold in-
crease in PIB uptake in the cortical area in cases of AD, in compared controls. Amyloid
PET is also informative in early AD and even MCI, where by amyloid positive MCI
individuals are at higher risk of developing dementia than those with a negative amy-
loid PET scan. PIB has been used in many other studies to investigate the amyloid
deposition association with PD, PDD and other neurological disorders. Recently, PIB
amyloid deposition has been associated with the rate of cognitive decline in PD. Gom-
pert et.al reported an increase in cognitive decline in PD individuals with low levels
of cortical amyloid deposition in comparison to individuals with amyloid free cortical
area (Gomperts et al., 2012). This finding has given us the push to further look into
understanding the amyloid association in PD .
These studies have shown the high efficiency and accuracy for indicating amyloid ac-
cumulation in the brain and have shown the high sensitivity of PIB as a diagnostic
marker in AD. However, PIB-C11 radiotracer has its limitations as it is unable to be
used as a clinical application, due to its short half-life of 20 minutes. To overcome
this limitation, other PET ligands have been developed and investigated, such as F-18
labelled tracers. Since F-18 tracers have a longer half-life of 110 minutes, they allow
regional distribution and clinical applications.
Villemagne et.al and others have shown the high accuracy and efficiency of FBB for
indicating amyloid accumulation in the brain and that it provides robust separation
between AD and healthy controls (Villemagne et al., 2012).
Degree of retention of FBB is lower than PIB. This means the dynamic standard uptake
value ratio of FBB is narrower. However, in the same study it was observed that both
tracers had high retention in the cortical grey matter and lower uptake in white matter
in those with AD. The ratio of frontal cortex to white matter ratio for PIB was 1.45 for
AD subjects (Villemagne et al., 2012).
Barthel and colleagues showed that the sensitivity and specificity of FBB is 80% and
91% respectively to distinguish AD subjects from a healthy control group (Barthel et
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al., 2011).
1.2.2 Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is a non-invasive technique which provides high
quality anatomical and functional images for a range of tissue types in the human body.
The MR system consists of: the superconducting magnet, radiofrequency coils and gra-
dient coils. Generally, the magnet used in MRI is a superconducting magnet (1.5 Tesla
or higher) and is used to generate a strong constant magnetic field. The radiofrequency
coil is made up of a transmit coil and a receiver coil. The transmit coil produces the
radiofrequency pulses (discussed in detail later in this section) and the receiver coil de-
tects the MR signals. The gradient coils produce small variations in the magnetic field
and allow localization of the image slice (Bushberg et al., 2002).
MRI principle of operation
The basic principles of MRI are based on the magnetic properties of the nucleus of the
hydrogen atom. Every atom has a property known as spin (Bushberg et al., 2002). The
hydrogen atom is the most abundant nucleus in the human body, due to water and
fat content. MRI uses these hydrogen atoms and its property of spin (Bushberg et al.,
2002). Due to spin, the hydrogen atoms produce a magnetic moment vector µ and act
as little magnets with weak magnetic fields (Mikla & Mikla, 2013). In nature, these
magnetic moment vectors are orientated at random.
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FIGURE 1.6: Orientation of hydrogen atom in nature (absence of external
Magnetic Field) and in the presence of an external Magnetic field. In the
absence of magnetic field the hydrogen atoms are orientated at random
and the net magnetization is zero. In the presence of external Magnetic
field, the atom orientate in two direction: parallel to the magnetic field
or anti-parallel to the magnetic field (as depicted by the direction of the
small arrows portraying the atom axis of spin) (Mikla & Mikla, 2013)
MRI manipulates these hydrogen atoms and their magnetic moment vector by using
an external magnetic field, in order to produce a net magnetization as shown in figure
1.6 (Mikla & Mikla, 2013). More precisely, when a magnetic field is applied in the MRI
system, the protons experience torque which causes the magnetic moment vector to
align with the magnetic field (Brown & Semelka, 2011). This also results in precession
of these vectors around the external magnetic field. There are two orientations in which
the protons align themselves in the presence of an external magnetic field: parallel
(spin-up) or anti-parallel (spin-down). The spin-up orientation is a low energy state
whereas the spin-down orientation is a higher energy state and so the majority of the
proton nuclei prefer to align themselves in the parallel orientation. More protons in the
spin-up orientation result in a net difference in the orientation of proton alignment and
this difference creates a net magnetization vector, parallel to the external magnetic field
(Brown & Semelka, 2011) (Mikla & Mikla, 2013).
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The frequency of proton precession around the magnetic field is governed by the Lar-
mor frequency w. The Larmor frequency depends on the strength of the external mag-
netic field (B) and the gyromagetic ratio γ of the tissue (equation 1.5) (Bushberg et al.,
2002).
w = γB (1.5)
In MRI, in order to acquire MR signals, the net magnetization (M) is manipulated by
applying a pulse of radio-frequency energy (RF pulse) at the resonant frequency of the
proton, perpendicular to the external magnetic field. The RF pulse is known as the
excitation pulse. This pulse allows the protons to absorb energy at a given frequency
and then re-emit energy at the same frequency. For an efficient MRI system, this pulse
is tuned to the Larmor frequency (processional frequency of the protons), resulting in
changing the energy levels of protons (Brown & Semelka, 2010). The proton absorbs
the RF energy and move from a lower energy state (parallel to the magnetic field) to
a higher energy state (anti-parallel to the magnetic field). The number of protons that
undergo this change depends on the RF pulse amplitude and duration, which ulti-
mately determines the net magnetization orientation (Weishaupt, Köchli, & Marincek,
2006)(Brown & Semelka, 2010).
In terms of macro-level, the net magnetization can be described on Cartesian coordi-
nate axis system (xyz plane). Initially the net magnetization is in the z axis which is
parallel to the applied magnetic field (B). This is due to a greater number of protons in
the lower energy state than the higher energy state. As the RF pulse is applied, with the
right amplitude, duration and resonant frequency, the net magnetization can be excited
and rotated to any desired angle (flip angle). For example, by applying the RF pulse
perpendicular to the external magnetic field, with a high enough amplitude and certain
duration, it will result in the net magnetization (initially in the direction of the external
magnetic field) rotating to the transverse plane (x-y plane). Initially, immediately after
the RF pulse is applied, all the nuclei spins are in phase in the transverse plane. When
the RF pulse is removed, three processes take place simultaneously. Firstly, the RF en-
ergy absorbed by the proton is re-emitted at the resonance frequency. Secondly, the
Chapter 1. Introduction 25
excited protons return to their original equilibrium position (z-plane orientation) by
the process known as T1 relaxation (spin-lattice or longitudinal relaxation). Thirdly, in
the x-y plane, the in-phase net magnetization (exited proton) begin to dephase, by the
process of T2 relaxation (spin-spin or transverse relaxation). The emission of the elec-
tromagnetic energy during the relaxation processes is eventually detected by a detector
in a MR scanner (Bushberg et al., 2002).
FIGURE 1.7: Manipulation of net Magnetization by applying a RF pulse.
The intensity of the MR signal received depends on the amplitude of the
RF pulse, the duration of the RF pulse and the Larmor frequency.(Harms
et al., 1984)
The T2 relaxation measures the energy transferred from one excited proton to another
nearby proton. During T2 relaxation, dephasing of the xy magnetization takes place.
This change in the magnetization induces an electromotive signal in the RF receiver
coil. This sinusoidal electrical signal is known as the free induction decay (FID) signal.
The FID signal depends on the amplitude of the net magnetization before the RF pulse
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is applied and the relaxation time. The amplitude of the FID signal decreases over time
in an exponential manner (eq. 1.6) (Bushberg et al., 2002).
M(t) = Mo(e−t/T2) (1.6)
As mentioned earlier, T1 relaxation process takes place simultaneously with T2 relax-
ation. During this process, the z magnetization return to the equilibrium in an expo-
nential manner (eq: 1.7) (Bushberg et al., 2002). T1 relaxation time measures the rate of
energy transferred from the excited nuclei to the environment (lattice), hence the name
spin-lattice relaxation (Bushberg et al., 2002) (Brown & Semelka, 2011).
M(t) = Mo(1− e−t/T1) (1.7)
The relaxation times T1 and T2 are different for different tissues; this allows the MR
system to identify different tissue based on their magnetic properties. In other words,
these relaxation mechanisms determine image contrast (Bitar, Leung, Perng, & Roberts,
2006). Tissues with longer relaxation times appear different to those with shorter relax-
ation time. For example, fat has a shorter T1 recovery time (recovery faster) and a
shorter T2 decay time (decays faster) in comparison to water, which has a longer T1
recovery time and T2 decay time. It is this recovery rate of signal that enables MRI
to differentiate between different tissue types and acquire clinical images (Bitar et al.,
2006) (Bushberg et al., 2002).
Data Acquisition and Image Formation in MRI system
To acquire an MR image, a pulse sequence is used, which is the timing and strength
of radiofrequency and gradient pulses used to determine the contrast of the image.
The FID signal is acquired indirectly by creating "echoes", or when a decaying signal is
refocused. In MRI, echoes can be generated in two ways, either by using a 180◦ (spin
echo) or by reversing the gradient polarity (gradient echo). In order to create echoes,
both of these methods rephase the spins which were initially dephasing after the net
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magnetization was rotated into the transverse plane. Once all the spins are in phase in
the transverse plane, an echo signal is generated. This echo signal is collected by the
detector in the MR scanner and is used to form an MR image.
A pulse sequence is basically a wave form with various magnetic gradients and RF
pulses. There are two fundamental types of pulse sequence: Spin echo (SE) and gra-
dient echo (GE). The other various pulse sequences are derived from these pulse se-
quences by adding different parameters to these pulse sequences to create images such
as T1 weighted image, T2 weighted, proton density and Fluid attenuation inversion
recovery (FLAIR) images. Different applications require different anatomical or func-
tional information and image contrast. To achieve this, certain parameters are ma-
nipulated in a pulse sequence. These parameters include: repetition time (TR), Echo
time (TE), Time of inversion (TI), RF pulse flip angle and gradients (Bitar et al., 2006)
(McRobbie, Moore, Groves, & Prince, 2007).
A basic pulse sequence requires a certain sequence of events in order to acquire signals.
In a basic pulse sequence, there are four sets of events which take place in order to
acquire an MR image. Firstly, a RF pulse is applied as shown by the top line in figure
1.9. At the same time, a slice selection gradient is applied in the z plane (second line in
figure 1.9). This is followed by a phase encoding gradient in the direction orthogonal
(y axis) to the slice selection gradient. The phase encoding allows encoding of the
phase of the MRI signal. Lastly, a frequency encoding gradient is applied in the x axis
during the decay of the echo; acquiring all the frequency information in the MR signal.
Simultaneous to the frequency encoding, data sampling and acquisition of the complex
signal take place (Bitar et al., 2006) (McRobbie et al., 2007).
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FIGURE 1.8: schematic of basic events in a SE pulse sequence. Initially,
an excitation pulse is applied, followed by switching on and off gradi-
ents (slice selection, phase encoding and frequency encoding); followed
by an inversion pulse to produce an echo (blue pulse) and finally signal
readout.(Hahn, 1950)
This data sampling and acquisition takes place using a one-dimensional Fourier trans-
form. The Fourier transform converts the signal into discrete frequency values and
corresponding amplitudes. It stores this information in a k-space matrix. The k-space
matrix is a two-dimensional matrix with positive and negative spatial frequency val-
ues. In the matrix, the x-direction represents the frequency encoded variables and the
y direction represents the phase encoded variables. Once the entire k space matrix is
filled, inverse Fourier transform in applied. It decodes the frequency domain variation
into a spatial domain (image) (Bushberg et al., 2002) (McRobbie et al., 2007).
Spoiled Gradient Recalled Echo Imaging
In this study, anatomical MR imaging was only used as the base for processing prior to
the statistical analysis. In this section we will focus on the gradient echo pulse sequence
as we used a T1- weighted spoiled gradient recalled echo (SPGR) image (Bushberg et
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al., 2002). A SPGR image provides a high resolution anatomical image which is in close
proximity to the tissue macroscopic image. It uses a gradient echo pulse sequence in
order to eliminate the transverse magnetization before applying the second RF pulse
(Hashemi, Bradley, & Lisanti, 2012). Since it eliminates the transverse magnetization by
using a shorter TE, it minimizes the T2 characteristics of the tissue. So SPGR obtain im-
age contrast by manipulating the TR and the flip angle. It uses shorter TR to minimize
the recovery of the longitudinal magnetization, thereby enhancing the T1 relaxation
characteristic of different tissues. Also, shorter TR allows faster image acquisition and
maximizes signal to noise ratio in the image (Hendrick, 2007).
T2 Weighted F luid Attenuation Inversion Recovery
T2 weighted Fluid attenuation inversion recovery (FLAIR) imaging is a unique imaging
pulse sequence which produce a strong T2 weighted image with suppressed fluid sig-
nal (Bushberg et al., 2002). This pulse sequence is most commonly used in neurological
imaging to exclude non-disease related pathology and to enhance signals from periven-
tricular lesions (Brant-Zawadzki, Atkinson, Detrick, Bradley, & Scidmore, 1996). It uses
conventional Spin Echo pulse sequence with a 180◦ inversion pulse and a prolonged
T1 recovery time. The longitudinal magnetization recovery time is set to the time it
takes for the cerebrospinal fluid (CSF) longitudinal magnetization to reach zero cross-
ing point. This will allow removing of the signal from CSF from the resultant image
(Brant-Zawadzki et al., 1996).
1.3 Image Preprocessing
Image preprocessing is a vital step in any medical imaging application. It is impor-
tant to minimize noise and sampling errors. The steps performed in image prepro-
cessing (discussed in detail in chapter 2) aim to process the data so that it is suitable
to be analysed statistically. In this study, image preprocessing was performed us-
ing statistical parametric mapping (SPM, University College London) software (http :
//www.fil.ion.ucl.ac.uk/spm/).
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FIGURE 1.9: Statistical Parametric Mapping 12
SPM is designed to facilitate image preprocessing and voxel-based analysis of struc-
ture, function and disease-related changes in the brain (Friston, Ashburner, Kiebel,
E.Nichols, & Penny, 2011). Image preprocessing using SPM is discussed in detail in
chapter2.
Chapter 2
Methodology
2.1 General Information
Fifty subjects with PD-MCI were either recruited from a local specialist movement dis-
order clinic or were volunteers from an ongoing longitudinal PD study at the New
Zealand Brain Research Institute. The demographic and clinical characteristics of the
participants are described in Table 2.1.
TABLE 2.1: Summary of demographic and clinical characteristic
Mean(SD) Range
Age(years) 73(6) 59-86
FBB dose (MBq) 300(17) 240-346
Clinical Characteristic
Hoehn and Yahr stage 2.56(0.56) 1.5-4
PD duration (years) 6.9(4.9) 1-20
UPDRS motor score 40.92(13.54) 13-68
Cognitive indices
MoCa score 21.78(3.67) 12-28
Attenuation Z score -1.02(0.76) (-3)-(0.53)
Executive Function score -1.14(0.74) (-2.64)-(0.72)
Learning Z Score -0.93(0.90) (-2.42)-(1.54)
Language Z score -0.52(0.68) (-2.56)-(0.64)
Visuospatial functional Z score -0.80(0.84) (-2.54)-(1.02)
Global Cognitive function Z score -0.98(0.64) (-2.44)-(0.62)
WAIS-III information subtest score 107(10) 86-125
PD dementia Risk Score 0.65(0.3) 0.04-0.99
The diagnosis of PD was performed using the UK Parkinson’s society criteria. Re-
cruited individuals had motor symptoms at least a year prior to study entry, to exclude
dementia with Lewy body cases. All subjects received a clinical evaluation, structural
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MR imaging and FBB PET imaging, along with cognitive assessments. Exclusion cri-
teria included prior neurosurgery for PD and medical conditions such as stroke, head
injury and learning disabilities. All subjects gave written consent. The study was also
approved by the Upper South Regional Ethics Committee of the New Zealand Ministry
of Health.
2.2 Neuropsychological Assessments
The neuropsychological assessment employed in this study was designed and per-
formed by members of the New Zealand Brain Research Institute (NZBRI). The as-
sessment, which takes anywhere from 2.5 - 5 hours to complete, is routinely used in
the assessment of patients cognition at the NZBRI. In this study, the NP battery was
performed to ensure that the subjects fulfilled the diagnostic criteria for PD-MCI; with
the different neuropsychological test scores also being obtained for statistical analysis.
The neuropsychological assessment was conducted in two sessions and it examines
five cognitive domains posed by the Motor Disorder Society-Task Force Level-II re-
quirement for PD-MCI (Litvan, Goldman, Tröster, et al., 2012). These four domains
were: executive function, attention/working memory, learning memory, language and
visuospatial/visuoperceptual skills. These domains were individually assessed using
different assessments. Executive function was assessed by examining the Stroop inter-
ference, letter fluency, category fluency, category switching, action fluency and trails.
Attention and working memory were examined by testing everyday attention, Stroop
colour reading, Stroop word reading, digits forwards/backwards and digit ordering.
The learning and memory domain were assessed using California verbal language test-
II short form (short and long delays) and the Rey complex figure test (short and long
delay). The visuoperceptual performance was measured using judgment of line ori-
entation, fragmented letters, the picture completion test and Rey complex figure copy.
Lastly, language was assessed using the Boston naming test, dementia rating scale-2
similarities sub-test and the Alzheimer’s Dementia assessment cognitive scale (Wood
et al., 2016).
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The scores obtained for these sessions were used in categorizing the participants ac-
cording to their cognitive statues (PD-N, PD-MCI and PDD) and to acquire a summary
of global cognitive ability,’Global cognitive Z score’ (discussed in more detail later in
this section). The categorizing was done using the MDS Task force criteria for MCI
(Litvan, Goldman, Tröster, et al., 2012)(-1.5 standard deviation (SD) below the norma-
tive data on at least two tests within one of the four domains) (Dalrymple-Alford et al.,
2011b) and PDD dementia assessment which incorporates an evaluation of everyday
function. MCI criteria required the individual had unimpaired daily functional activ-
ities but met the operationalized criterion of impairment of 1.5 standard deviation or
below the normative data in at least two of the five MDS cognitive domain assessments.
From these scores a global cognitive Z score was obtained by averaging the score from
the MDS cognitive domains excluding the language domain scores (Litvan, Goldman,
Tröster, et al., 2012).
2.3 Magnetic Resonance Imaging
All subjects underwent an MRI scan. The scan was conducted using a 3T GE HDxt
MR scanner with an eight channel head coil, at Hagley Radiology. The 3T Magnetic
field scanner provides stronger signals, enables high quality images to be acquired at a
faster rate, with high resolution and good contrast. The structural T1-weighted images
were obtained for image preprocessing of the PET images and T2 Flair images were
obtained to quantify white matter hypertensity volumes.
2.3.1 Scanning protocol
The structural MR images were acquired using a T1-weighted, three dimensional spoiled
gradient echo (SPGR) acquisition with following parameters: TE = 2.8ms,TR = 6.6ms,
TI = 400ms, flip angle = 15◦, acquisition matrix = 256 x 256 x 170, Field of View (FOV)
= 250mm, slice thickness = 1mm, voxel size = 0.98 X 0.98 X 1.0mm3, scan time = 5 min
and 6 sec.
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T2 Flair images were acquired with the following parameters: TE = 104.5 msec, TR =
9000 msec,TI = 2250 ms, Flip angle = 90◦, reconstruction matrix = 512 x 512 x 32, FoV =
220 mm, slice thickness = 3 mm, and scan time = 2 min 56 sec.
2.4 Positron Emission Tomography
All the subjects were scanned using a GE discovery 690 PET scanner at Southern Cross
hospital. Subjects were injected with 300 MBq of F18- Flurobetaban (FBB), prepared
at Cyclotek Ply Ltd (the major supplier of PET radio-pharmaceuticals) in Melbourne,
Australia. It was ensured that the radioactive exposure of FBB to the patient was un-
der the recommended radiation exposure of 300 ± 20% MBq and the tracer dose was
under 55 µg per injection. Prior to the PET scan, a computer tomography transmis-
sion scan was obtained for each individual to perform attenuation correction by the
PET/CT scanner. Time of flight and attenuation correction was applied by the scan-
ner during image reconstruction at the time of scanning. Time of flight was obtained
using the iterative Time of Flight plus the SharpIR algorithm. SharpIR is an iterative
reconstruction method employed by general electric (GE) company to reconstruct PET
images (Ross & Stearnsr, 2016).
During image reconstruction, two types of images were obtained: Time of Flight with
Attenuation Correction image (TOFAC) and Time of Flight with No Attenuation Cor-
rection (TOFNAC). The purpose of obtaining these images is discussed in detail in
section 2.5.2.
All the subjects were placed in the scanner with head pads and neck support to ensure
that the patients would be comfortable and that their head would be kept still for 20
minutes (duration of the scan). The CT was acquired first (to facilitate attenuation
correction). The PET acquisition was obtained 90 minutes post injection of FBB, with
an acquisition time of 20 min. For the CT, the direction of the scan was caudocranial
with 120 kV and 30 mA. The PET and CT images were reconstructed with the following
parameters: Slice thickness of 3.75 mm; Slice interval of 3.27mm; Field of View (FoV)
of 50cm; Pitch of 0.969:1 and Rotation time of 0.5 second. In order to acquire TOFAC
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images during the reconstruction process, the SharpIR algorithm was applied, with a
reconstruction resolution of 3 mm full width half maximum (FWHM); 16 subsets and
4 iterations. For TOFNAC images all the parameters were kept the same except no
attenuation correction was applied.
2.5 Image Preprocessing
Image preprocessing is a vital step in any medical imaging application, prior to any
statistical analysis. It enhances the visual appearance of images and transforms the
raw data into a version which is easier to work with and perform statistical analysis
on.
In this study, it was used to remove noise, correct for artefacts and eliminate patient
motion. It also ensured that the brains of all participants were registered, i.e. each
voxel in the image corresponds to the same region in the brain of each individual.
This allows accurate group analyses by normalising each individual brain image into a
standard space.
In this study, image preprocessing was performed by using Statistical Parametric Map-
ping (SPM12) (Welcome Department of Cognitive Neurology, University College Lon-
don,UK) in MATLAB versions 7.4 (R2014a, Mathworks, Massachusetts, USA).
Initially, all the images (MR and PET) were converted from their original file format
Digital Imaging and Communications in Medicine (DICOM) into single Neuroimag-
ing Informatics Technology Initiative (NifTI) format files, since SPM operates on NifTI
format files (Friston et al., 2011).
2.5.1 Magnetic Resonance Image Preprocessing
The preprocessing of structural images included bias correction, normalisation of the
structural images, tissue classification and removal of non-brain tissue. Using SPM 12
allowed us to perform these steps using a single model, developed in 2005 by Ash-
burner and Friston, known as the Unified segmentation (AshburnerT & Friston, 2005).
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Using this model, T1-weighed SPGR images were tissue classified. This partitions the
structural image into voxels containing grey matter, white matter, cerebrospinal fluid
(CSF) and skull using tissue probability maps (TPM), as shown in Figure 2.1.. Then
combines dartal normalisation and bias correction with tissue classification.
FIGURE 2.1: Segmentation of structural image into A. Grey matter; B.
White matter and C. Cerebrospinal fluid
Before using these prepossessed structural images for further image preprocessing,
segmented volumes were visually inspected to ensure that they were accurate and
contain no gross errors. In order to acquire, white matter hyperintensity (WMH) le-
sion volumes, the lesion segmentation toolbox, 20 was employed. This toolbox looks
for T2 hyperintensities in the T2 FLAIR images and T1-weighted image. This derived
a WMH lesion volume for our fifty participants. This WMH lesion volume was used
to see an association or interaction of amyloid accumulation with WMH.
2.5.2 Positron Emission Image Preprocessing
The initial step of PET image preprocessing was to eliminate motion effects. Motion
artefact in brain imaging is a serious problem in terms of image quality. It is important
to minimize motion from the scans for analysis, especially in the case of brain study.
From previous studies (associated with amyloid accumulation in PDD and AD), it has
been understood that the abnormal amyloid accumulation in PD is in the cortical grey
matter of the brain. Any motion present in the scan can cause inaccurate analysis, as
the area of interest (cortical grey matter) is only 4 millimetres thick. Furthermore, due
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to motion, the signal from the white matter could be mistakenly taken as the signal
from the cerebral cortical area.
Even though we try to ensure that there is no head motion during the scans, it is im-
possible to eliminate head motion from the scan during scanning. This is because our
participants have PD with motor symptoms such as tremor at rest. Therefore, in order
to acquire a high image quality and accurate analysis of amyloid accumulation in the
cortex, motion is eliminated from the images during the image preprocessing step.
In this study, two approaches were taken for motion correction, from which the most
effective method was chosen. For both approaches, it was important to reconstruct
the single frame of 20 minute dynamic scan into four frames of 5 minute scans. Dur-
ing PET scanning two types of images were taken as discussed in the PET scanning
protocol TOFAC and TOFNAC. In the first method, the motion correction was applied
prior to attenuation correction, so TOFNAC images were used. In the second method,
motion correction was applied after attenuation correction, so TOFAC images for pre-
processing were used.
FIGURE 2.2: Motion correction. A. a single frame of 20 minute dynamic
scan. B. Realigned and summed image of four frame of 5 minute scans.
Note: B has minimised motion which provide much ore clear regional
uptake in comparison to A.
We used SPM 12 Realignment and Reslice processing to eliminate motion. The step
realigns the volumes to a reference image. Generally, the reference image is the first
volume imported in the time series. For example, in our case it took the first 5 minute
frame image as the reference image and realigned the remaining three 5 minute frames
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to the first frame using a least squares approach and a six parameter rigid body trans-
formation. This reduces motion and increases signal to noise ratio (SNR). During the
realignment process, a text file and plots were generated which provide an estimate of
the transitional, x-, y- and z- direction ("right", "forward", "up"), and estimated rotation
("pitch","roll","yaw") as in Figure 2.3. For each individual, the plots were examined to
make sure that the estimate transition in all three directions was less than 4 millimetres.
This method of motion correction can only correct for motion of about 4 millimetres. In
this study, any individual with motion greater than 6 millimetres translation or 5 ◦ was
excluded from the study (Friston et al., 2011).
FIGURE 2.3: Realignment and reslicing
Once all four frames were realigned, the images were summed to generate a single
frame (Figure 2.2). Once the summation process was over, in the case of the second
method, the TOFAC image was ready to be used for further preprocessing. However,
in the case of the first method, the TOFNAC images underwent attenuation correc-
tion using a MATLAB 7.4 script file (Appendix A). The script file applied attenuation
correction to the motion corrected TOFNAC images, by using attenuation coefficient
maps and reconstructed an image using the radon transform. Radon transform is a
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tomographic reconstruction method that calculates the sum of pixel intensity in each
direction (line integral). It maps an image from the Cartesian coordinates to polar co-
ordinates (x’, θ) (MathWorks, 2015). One drawback with this method was that by us-
ing radon transform, the image quality was reduced (Figure2.4). Due to this reason,
the second method was used throughout the study for motion correction. The second
method provided excellent image quality and also the desired information for statisti-
cal analysis.
FIGURE 2.4: Attenuation correction of PET motion corrected image us-
ing Radon transform.
Once the images had undergone motion correction, they were co-registered to the
downsampled structural SPGR images. Since the positioning of the subject during an
MR scan and PET scan is slightly different, it is important to co-register the structural
image (SPGR MR Image) to the summed functional image (PET image).
Once all the volumes were in the same origin as the structural volumes, all the images
underwent Normalisation. Normalisation is a non-linear registration process which
spatially transforms the data into a standard space for future analysis. This allows us to
reduce variation in brain images from each individual (while maintaining difference of
interest) allowing meaningful group comparisons to be performed successfully. Here,
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normalisation was conducted in two sets: DARTEL Normalisation and warping the
images into standard space.
Diffeomorphic Anatomical Registration through Exponentiated Lie Algebra (DARTEL)
Normalisation is a non-linear image registration process which matches individual im-
ages to the Montreal Neurological Institute (MNI) template. Templates are pre-existing
images to which our individual images are aligned. These templates contain informa-
tion about the location of the anatomical features in the MNI coordinate space(Friston
et al., 2011). DARTEL normalisation creates a template by warping the segmented
structural grey matter and white matter images together for each individual (Figure
2.5). This template is used as a deformation field for warping other images which are
not in the MNI space but images must be aligned with structure MRI, hence the coreg-
istration of the summed PET image to the structural MRI.
FIGURE 2.5: DARTAL Normalisation from fields, i.e. how a voxel must
be warped to align with standard space(defined here as MNI-SPACE).
The second part of normalisation (applying the deformation fields), allows generation
of spatially normalised images by warping the non-structural images and segmented
images. In this study, the segmented grey matter images and PET images for each in-
dividual were normalised using the deformation fields (generated in the first step of
normalisation) for each individual. In this step, we modulated the grey matter seg-
mented images and left the PET images unmodulated. The reason the grey matter im-
ages were modulated was to compensate for the effect of spatial normalisation. During
spatial normalisation, volumetric differences are introduced and this can alter the to-
tal amount of signal in the voxel. Modulation to the grey matter images, preserve the
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total amount of signal in the normalised segmented images. On the other hand, in the
case of the PET images, unmodulation helps preserve the concentration of signal in
the volume. Before data analysis was performed, all normalised images were visually
examined to ensure that they were accurate and were not grossly mis-aligned.
2.6 Data Analysis
To evaluate the PET images and compare the FBB retention across individuals, a Stan-
dard Uptake Value (SUV) was calculated for all voxels. SUV is defined by the concen-
tration of radioactivity in the Region of Interest (ROI) in the PET image, normalised for
the injected dose and body weight of an individual (Equation 2.1).
SUV =
Concentration
Injecteddose
(bodyweight) (2.1)
In this study, the SUV was calculated using the preprocessed FBB-PET images in stan-
dard space (MNI-space). Standard Uptake Value Ratio (SUVR) were acquired using
the cerebellar cortex as the reference region. In each individual the cerebellum cortex
was defined as the union of the Harvard-oxford cerebellar atlas and the segmented
grey matter map (in each individual; Appendix B). The SUV at each voxel was divided
by the mean FBB signal in the cerebellar cortex, producing SUVR values at each voxel.
These SUVR images were the images analysed in this thesis. They represent the rela-
tive accumulation of amyloid in each individual, normalised to uptake in the cerebellar
cortex.
2.6.1 Clinical Amyloid Diagnosis
FBB PET images of all the subjects were clinically assessed by a specialist neuroradiol-
ogist from Christchurch Radiology Group (Ross J Keenan). The assessment was con-
ducted using the Standard GE healthcare clinical inspection reporting form designed
for [18-F]-Flutemetamol PET image. This was performed using COMRAD Radiology
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Information System (RIS) which is a comprehensive workflow software. FBB positiv-
ity was evaluated in five cortical regions: frontal lobes, posterior cingulate/precuneus,
temporal lobes, parietal lobes and striatum. The scans were considered either positive
(FBB(+)), equivocal or negative (FBB(-)).
Positivity was based on the amount of signal in the five cortical regions and also the
visibility of gyrus, midline (bleeding of signal), precuneus and striatum gap in these
regions. A positive FBB image was defined as high accumulation of amyloid in the
cortical region of the brain in comparison to the white matter. Whereas, a negative FBB
image was defined by no amyloid accumulation in the cortical regions of the brain.
2.6.2 Statistical Analysis
Statistical analysis was performed using the smoothed SUVR images obtained from
each subject. The SUVR images were smoothed using an isotropic Gaussian kernel
with FWHM of 8 mm. Smoothing suppresses noise and reduces the effects due to
residual misalignment. Using the smoothed SUVR images, the uptake ratio for 5 corti-
cal regions of interest (whole cortex, frontal lobes, posterior cingulate/precuneus, tem-
poral lobes, and parietal lobes) and three subcortical regions (striatum, putamen and
thalamus) was calculated. These 8 regions were defined by the Harvard-oxford cor-
tical and subcortical probabilistic atlases. In addition, we employed a multivariate
analysis of FBB-PET data set to identify a pattern of uptake associated with amyloid
deposition. We used linear regression (lm in R studio version 3.0.2) to investigate the
association between ROI SUVR and Cog Z (averaging the score from the MDS cog-
nitive domains excluding the language domain scores)/PDDRS (Parkinson’s disease
dementia "risk" score, predicted the probability of risk that an individual has of con-
verting to dementia in the next 4 years); with age, sex and UPDRS (motor impairment
scale) as co-variates. We also checked for a significant group-by-Cog Z/PDDRS inter-
action, to investigate whether the FBB(+) group behaves similarly to the FBB(-) group.
The comparisons were considered significant if p<0.05. The two multivariate methods
I employed were principal component analysis (PCA) and independent component
Chapter 2. Methodology 43
analysis (ICA). Lastly, I applied bootstrapping to provide an estimate of the reliability
of the identified network.
Principal Component Analysis
Principal Component Analysis (PCA) is a multivariate data analysis technique that has
been used in many applications such as face recognition, image compression and find-
ing pattern in large data sets (Rencher & Christensen, 2012). It uses an orthogonal
linear transformation technique which transforms the original correlated data set into
a new coordinate system which provides information about the variance in the data
set (Rencher & Christensen, 2012). It does this by extracting main source of variation
in the data set. These variations are expressed as vectors (known as Principal Com-
ponents or PCs)(Figure 2.6). These projections (PCs) are orthogonal to each other and
uncorrelated. These projections highlight the similarities and differences in the high di-
mension data set. In order to acquire the variance projection data using PCA, initially
the mean of the data set is subtracted from the data set (between and within subjects).
For example, our data set is represented by Matrix A(m, n) where m is the number of
participant and n is the number of voxels (the ID representation of the 3D image). I
firstly, subtracted m¯ from the m values and n¯ from the n values. This results in a matrix
of values with a mean of zero (Rencher & Christensen, 2012). This is further used to
calculate the covariance matrix as shown in Equation 2.2. The covariance determines
how much variation is present in each dimension with respect to the mean of the data
set.
cov(X,Y ) =
∑n
i=1(Xi − X¯)(Yi − Y¯ )
n− 1 (2.2)
Once the covariance matrix was calculated, the eigenvalues and eigenvectors were de-
termined. The eigenvectors and eigenvalues provide useful information about our
data. The eigenvectors corresponds to the principal components and the eigenvalues
associated with each eigenvector, yield the fraction of variability explained by each
principal component (Rencher & Christensen, 2012).
44 Chapter 2. Methodology
In matrix form these principal components are expressed as:
P = SV (2.3)
Where P is the principal components of the original data set (V ) and S is the eigenvec-
tor matrix, which rotates and stretches the V matrix into P matrix (Stühler & Merhof,
n.d.) . Using the scaled eigenvectors (that represent the expression of each principal
components in each participant), principal component images were generated. Fur-
thermore, the eigenvectors were transposed to acquire principal components score for
each participant (Stühler & Merhof, n.d.).
FIGURE 2.6: principal Component Analysis: A. 3D representation of a
brain image for a person ; B. Representation of data after transformation
of X subject by Y voxels, where each 3D image has been converted into a
1D vector ; C. Example plots of expression of the first 3 PCs i.e. the eigen-
values in each individual associated with each of the eigenvectors,PCs
(Stühler & Merhof, n.d.)
One of the advantages of PCA is that it provides the information of the maximum vari-
ance in the data set in the first few principal components. So for a large data set such
as our where the dimension depends on the number of participants and the number of
pixels, PCA makes it easier to interpret and analyse the data. More specifically, the first
principal component contains the maximum variance followed by the second compo-
nent and so on.
PCA has been previously used as a statistical tool in a number of studies associated
with neurological disorders, including both PET and MRI studies of PD and AD. In this
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study, I employed voxel-based PCA to identify the pattern of variance in FBB deposi-
tion, to highlight regions with high amyloid accumulation. Using the PC score, we also
looked at the correlations between amyloid accumulation and global cognitive score
and neurological test score, along with the visual assessment. After performing PCA, I
investigated the first N components that explained more than 66% of the variance. This
was done using logistic regression; identifying PCs that were associated with amyloid
positivity (as defined by the clinical diagnosis). These PCs were then used to create
an amyloid positive network, formed as a linear combination of PCs that significantly
contributes to the prediction of amyloid positivity. We then calculated the expression
of this amyloid network, the network score and investigated whether this score was as-
sociated with global cognitive score, motor impairment(UPDRS3), WM hyperintensity
volume, age or sex.
Independent Component Analysis
To see similar or different patterns of amyloid accumulation as seen in PCA, Indepen-
dent Component Analysis (ICA) is a linear transformation technique (Comon, 1994).
However, ICA allows non-Gaussian data analysis so that the components are statisti-
cally independent. It is most commonly applied for data compression, Bayesian detec-
tion, source localisation and deconvolution (Comon, 1994).
In ICA, the weighting matrix is determined slightly different to PCA, which is rep-
resented by the inverse of the matrix S in equation 2.3. Since the components are
statistically independent, one component doesn’t give any information about another
component. This is slightly different than PCA because PCA seeks for components
that best represent the data set whereas ICA seeks for components that are most in-
dependent from each other. ICA provides independence for non-Gaussian data sets.
I performed ICA using The FastICA package (free (GPL) MATLAB program)(http :
//www.cis.hut.fi/projects/ica/fastica/) that uses the Hyvarinen’s fixed point algo-
rithm (Hyvärinen & Oja, 2000).
ICA has been previously used in studies using functional MRI in AD, looking at al-
terations in memory networks in MCI (Celone et al., 2006). Similar to PCA, I applied
46 Chapter 2. Methodology
ICA on our data set to acquire components associated with amyloid accumulation in
different regions of the brain. I then used linear regression to determine whether any
ICs were associated with Cog score, motor impairment, age or sex.
Bootstrapping
Bootstrapping is a statistical non-parametric technique (Han & Luos, 2014). The pur-
pose of bootstrapping is to estimate the accuracy of a sample statistic. It is virtually
impossible to analyse the whole population; instead, we have a sample of the popula-
tion which may not give a true distribution of the whole population. The validity of
our sample set is unknown and the sample set could be biased. To overcome this issue
of a biased sample set, we apply bootstrapping. It uses a Monte Carlo method and
resamples the data set (as shown by the overview of bootstrapping in figure 2.7)
FIGURE 2.7: Overview of Bootstrapping. a. bootstrapping creates speci-
fied number of resampled sets with the same size as the subsample from
the population while using replacement from the subsample. (Han &
Luos, 2014)
It resamples the data with replacement, for a specified number of times, while keep-
ing the sample size the same (in this case the sample size remains 50 participants).
Also, it computes the distribution of the estimates to the original sample set. One
of the differences between bootstrapping and other resampling methods is that it al-
lows duplication of a participant in a given resampled set. I created a bootstrapped
amyloid network for each of the 5000 resampling. This provided an estimate of the
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population mean and standard deviation. A z-scored mean was then approximated
by dividing the sample network (already determined) by the bootstrapped standard
deviation. This image was thresholded at Z = - 1.96 and + 1.96, corresponding to p <
0.05 for display purposes.

Chapter 3
Results
3.1 Clinical Amyloid Diagnosis
Of the 50 PD-MCI participants, 9 received a clinical classification of FBB positive, 2
equivocal, and the remaining 39 were clinically amyloid-negative (FBB(+)). These clin-
ical classifications were used in the quantitative analyses. In all further analyses, the 2
equivocal clinical cases were treated as amyloid-positive (FBB(-)).
Figure 3.1 shows an example of a clinically positive FBB scan (left) and a negative scan
(right). The negative amyloid scan characteristically showed FBB uptake in deep white
matter without any relevant FBB uptake in the cerebellar grey matter. The positive
amyloid scan had FBB retention in the neocortex region from the reference region (cere-
bellum cortex).
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FIGURE 3.1: Example of FBB PET axial, sagittal and coronal images over-
laid on the co-registered MR structural image, representing: A. Clinical
positive amyloid scan and B. Clinical negative amyloid scan. Colour Bar
represent the standard uptake value ratio (cerebellar cortex). The Posi-
tive amyloid scan clearly show higher FBB retention in the cortical area
of the brain in comparison to the negative amyloid scan. The colour
bar also displays the scaling of Standard uptake value ratio (red is high
uptake and blue/black is low uptake).
3.2 Regional FBB Retention in PD patients
The mean and range of FBB retention in each region of interest (ROI) is reported in
Table 3.1.
TABLE 3.1: Summary of regional FBB SUVRs
Mean(SD) Range
Neocortical (global) 1.16(0.19) 0.82 - 1.79
Frontal cortex 1.08(0.24) 0.65 - 1.82
Temporal cortex 1.24(0.25) 0.77-2.06
Posterior Cingulate and Precuneus 1.26(0.29) 0.933 - 2.4
Thalamus 1.10(0.16) 0.71-1.5
Putamen 1.45(0.20) 1.18-2.4
Caudate Nucleus 0.79(0.12) 0.54-1.10
SUVR values were significantly higher for the FBB(+) group relative to the FBB(-) group
across the entire cortex; especially in the frontal cortex, temporal cortex, anterior and
posterior cingulate gyri and subcortical regions; precuneus and putamen (Table3.2).
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However, there were no significant differences observed between the FBB(-) and FBB(+)
group in the caudate nucleus and thalamus (Table 3.2).
TABLE 3.2: Quantitative PET data analysis by brain region
FBB(+)group
Est.mean SUVR
( 95% CI)
FBB(-)group
Est.mean SUVR
(95 % CI)
Mean Difference
(95% CI)
T,p
Neocortex 1.44[1.37 - 1.5] 1.08[1.04 - 1.11] 0.36[0.28 - 0.44)] 9.67, p<0.00001
Frontal Cortex 1.37[1.25 - 148] 0.99[-0.94 1.06] 0.37[0.24 - 0.50] 5.76, p<0.00001
Temporal Cortex 1.62[1.52 - 1.72] 1.14[1.09 - 1.19] 0.48[0.37 - 0.59] 8.739, p<0.00001
Occipital Cortex 1.21[1.11 - 1.33] 1.1[1.05 1.17] 0.11[-0.015 - 0.24] 1.764, 0.0841
Anterior Cingulate 1.59[1.51 - 1.67] 1.19[1.15 - 1.23] 0.40[0.31 - 0.49] 8.882, p<0.00001
Posterior Cingulate 1.68[1.57 - 1.79] 1.19[1.14 - 1.26] 0.48[0.36 - 0.61] 7.90, p<0.00001
Precuneus 1.68[1.58 - 1.79] 1.13[1.08 - 1.19] 0.55[0.43 0.67] 9.27, p<0.00001
Caudate Nucleus 0.82[0.75 - 0.89] 0.78[0.75 - 0.83] 0.032[-0.05 - (0.12)] 0.79 , 0.44
Putamen 1.68[1.59 - 1.77] 1.39[1.34 1.44] 0.29[0.19 - 0.40] 5.63, p<0.00001
Thalamus 1.15[1.05 - 1.25] 1.07[1.02 - 1.13] 0.076 [-0.03 -(0.18)] 1.39, 0.17
The estimated means for each group [95% CI] are reported in Table 3.2, along with the
estimate of the differences in the means between the two groups which were derived
using the lm function in R studio (version 3.0.2) (https : //www.rstudio.com/). R stu-
dio is a statistical computing and graphic software employed in this study to perform
statistical analysis. The T and P values of the differences between the group means are
reported. Results from the ROI analyses are presented as Boxplots in Figure 3.2.
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3.2.1 Association of Global Amyloid Burden with Clinical and Neuropsy-
chological scores.
We further investigated the relation between the SUVRs (regional and global) and the
cognition parameters of the neuropsychological tests (i.e. global cognition Z score (a
measure of global cognitive ability derived from the entire neuropsychology battery),
MoCa score (cognitive assessment), individual cognition domain score (attention, ex-
ecutive, learning, language and visuospatial) and the Parkinson’s disease dementia
"risk" score (PDDRS) (Table 2.1). PDDRS is a Gaussian Process model used to acquire
the probability of conversion to dementia within the next four years. This model was
trained on an independent group of PD patients followed over four years and is based
on age, MoCa and the test from the neuropsychology battery. Based on this model,
the PDDRS was calculated in every PD-MCI patient. We chose the global cognitive Z
score because it provides the best summary measure of the 4-6 hours of neuropsychol-
ogy battery. To further understand the association between our data and cognition, we
chose to look at each individual cognitive domain scores separately.
In the case of cortical and subcortical regional SUVRs, there was no evidence of corre-
lation between sex (p-value = 0.56 and CI95: [-0.09 - (0.17)]), age (p-value = 0.17 and
CI95: [-0.003 - (0.01)]), MoCa (p-value = 0.31 and CI95:[1.012 - (2.00)]), global cognition
Z score (p-value = 0.94 , CI95:[-0.86 - (0.081)]) and PDDRS (p-value = 0.85 , CI95:[-0.13
- (0.64)]).
However, there was a group-by-Cog Z interaction, for the Amyloid-positive group,
some of the regions SUVRs were slightly, but significantly, correlated with Global cog-
nition Z score (CogZ) (Table 3.3). These regions were: Neocortical (Figure 3.3A), an-
terior cingulate, posterior cingulate and precuneus (Figure3.4A). These same regions,
except for the precuneus, also showed a significant interaction with PDDRS (Table 3.3).
For all these region, the correlation between SUVR and global cognition Z score was
negative; meaning that the higher the retention of FBB in a given region, the lower the
cognition Z score was in the FBB(+) group. No significant correlation between SUVRs
and global cognition Z score were found in the FBB(-) group (Figure(3.3a)). The corre-
lation between the SUVRs for the aforementioned regions and PDDRS were positive,
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which shows that with an increase of FBB retention in a given region, the probability of
a future dementia increases (Figure (3.3c)). Another observation made for only the clin-
ical amyloid-positive individuals, was that there was a significant correlation between
SUVRs in the composite cortical, posterior cingulate and anterior cingulate regions and
MoCa test score. For all three regions the association in the FBB(+) group was highly
significant: cortical region (p = 0.004, CI95:[-0.05 -(-0.011)](figure3.3B), posterior cin-
gulate (p = 0.02, CI95:[-0.083 -(-0.0075)]) and anterior cingulate(p = 0.01, CI95:[-0.065
-(-0.009)]). Similar to the global cognition Z score correlation for FBB(+) group, the cor-
relation between these regions and MoCa was negative. No significant correlation was
found in the FBB(-) group.
FIGURE 3.3: Plots of interaction between FBB group and (A.) Global
Cognitive Z score (B.) MoCA Score (C.) Parkinson’s Disease Dementia
Conversion Score. Across all 3 measures, there was a significant interac-
tion. The FBB(-) group showed no association with cortical SUVR, while
the FBB(+) group showed a significant association with CogZ, MoCa and
PDDRS.
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FIGURE 3.4: Association between the Precuneus FBB uptake (SUVRs)
with (a) the Global cognition Z score and (b) Parkinson’s Disease De-
mentia "conversion" score.
There were however, no significant association or interaction found between regional
SUVRs in the caudate nucleus (Figure 3.6), putamen Figure(3.5), or thalamus, and
PDDRS and Global cognitive Z score (Table 3.3).
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FIGURE 3.5: Non-significant association between the Putamen FBB up-
take (SUVRs) with CogZ and Parkinson’s disease dementia "conversion"
score.
TABLE 3.3: Regional SUVR group-by-cog score interaction correlation
for Clinically classified Amyloid-positive participants with Parkinson’s
Disease Dementia conversion score and Global cognitive Z Score
PDDRS Correlation
T(p-value)
Global Cognitive Z Score
T(p-value)
Neocortex 1.70(0.09) -2.42(0.020)
Anterior Cingulate 1.71(0.009) -1.71(0.084)
Posterior Cingulate 1.14(0.26) -1.95(0.057)
Precuneus 1.24(0.10) -2.09(0.043)
Caudate Nucleus 0.26(0.79) -0.24 (0.8)
Putamen 0.66(0.08) -1.23(0.22)
Thalamus -0.07(0.94) -0.48(0.63)
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FIGURE 3.6: Association ( not significant) between the Caudate Nucleus
FBB uptake (SUVRs) and (A) Global Cognitive Z Score and (B) Parkin-
son’s disease dementia "conversion" score.
3.3 Principal Component Analysis
PCA was applied to identify the pattern of regional FBB uptake (amyloid accumula-
tion) in PD-MCI. From the PC analysis, the first five components were investigation,
which cumulatively explained 68.9% of the variance in the data. Principal components
1, 2, 3 ,4 and 5 explained 30.3%, 16.9%, 11.8%, 6.2%, 3.8% of the variance, respectively.
Axial, sagittal and coronal slices of all five PCs are illustrated in Figure 3.7. The first
principal component showed a significant difference between the FBB(+) group and
FBB(-) group and was characterized by increased FBB retention in the cortex (Figure
3.7a). The second component showed the difference between the FBB(+) and FBB(-)
group through increased FBB retention in the preforntal cortex, anterior cingulate, pos-
terior cingulate and the temporal cortex (Figure3.7B). The third component was driven
from the variation within the white matter and FBB retention in the brainstem, thala-
mus, putamen and caudate nucleus (Figure 3.7C). The fourth component highlighted
the relative difference between the frontal cortex and the rest of the brain (Figure 3.7D).
Finally, the fifth component demonstrated specifically the FBB retention in the thala-
mus (Figure 3.7E).
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3.3.1 Principal Component association with Clinical classification and Neu-
ropsychological score
The association of the five principal components was with the clinical classification,
illustrated in Figure 3.8.
FIGURE 3.8: Association between the Principal Component and the clin-
ical classification
A stepwise logistic regression identified three components (PC 1, 2, 3) to be signifi-
cantly associated with the clinical FBB groups (Table 3.4).
We applied multiple regression using age, sex, disease duration, UPDRS-III, CogZ/PDDRS
to the first five principal components. In the case of principal component 1 (PC1): there
was no correlation with the global cognitive z score or the PDDRS.
However, there was a significant association with age (t = 3.605, p = 0.0007, CI95:[3.1
-(11.1)]), sex (t = 2.023,p = 0.05, CI95:[0.04 -(12.6)]) and UPDRS (t = 2.64, p = 0.011,
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TABLE 3.4: Association between the FBB group and the PC scores
Mean difference between
FBB_groups(SD)
T,p
95% confidence interval
[CI95]
Principal Component 1 14.70(2.30) 6.28(9.34e-8) [9.99-19.40]
Principal Component 2 5.65(2.21) 2.55(0.014) [1.20-10.09]
Principal Component 3 5.13(1.82) 2.81(0.007) [1.45-8.80]
Principal Component 4 -0.23(1.43) -0.16(0.87) [-3.10-2.64]
Principal Component 5 1.09(1.11) 0.99(0.33) [-1.13-3.33]
CI95:[0.05 -(0.42)]). Furthermore, when looking at the amyloid-positive group PC1
score, found a significant negative correlation with both the learning domain (t = -2.59,
p = 0.013, CI95:[-12.68- (-1.57)]) (Figure 3.9A) and the MoCa score (t = -2.18, p = 0.035,
CI95:[-2.87 - (-0.11)]) (Figure 3.9B).
FIGURE 3.9: Principal Component 1 score correlation with (A) Leaning
Domain score (r = 0.58, t = -2.59, p = 0.013, CI95:[-12.68-(-1.57)]) and
(B)MoCa Score (r = 56, t = -2.18, p = 0.035, CI95:[-2.87 - (-0.11)]).
In the case of principal component 2 (PC2), there was no correlation with age, sex , UP-
DRS, the global cognitive Z score or PDDRS. However, the amyloid positive group PC2
score showed a significant negative correlation with the executive domain (r = 0.45, t =
-2.86, p = 0.007, CI95:[-16.06 -(-2.77)]) (Figure 3.10).
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FIGURE 3.10: Principal Component 2 score correlation with Executive
Domain score (r = 0.45, t = -2.86, p = 0.007, CI95:[-16.06-(-2.77)])
In the case of principal component 3, there was a slight, but significant correlation with
sex (t = 1.98, p = 0.05, CI95:[-0.05-(7.84)]). For principal components 4 and 5, no corre-
lations were observed with any of the cognitive parameters. However, an interesting
correlation was observed in the case of principal component 4 (PC4). PC4 showed sig-
nificant negative correlation with white matter hyperintensity lesion volume (r = 0.16,
t = -2.73, p = 0.009, CI95:[-2.94 -(-0.44)]) (Figure 3.11).
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FIGURE 3.11: Principal Component 4 score correlation with White mat-
ter hyperintensity lesion (r = 0.16, t = -2.73, p = 0.009, CI95:[-2.94 -(-0.44)])
3.3.2 Clinically Classified Amyloid-related Network
Since the first three components were significantly associated with the clinical classi-
fication, a linear combination of these components was used to form a network. This
network, gives a better representation of amyloid deposition than a single PC in this
sample. To acquire this network score, linear regression was employed (equation3.1).
The β parameters ( β = 0.0307, -0.0212, 0.0275) were taken from the results of the step-
wise logistic regression (FBB group was taken as the dependent variable and the PC1,
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2, 3, 4 and 5 scores were the independent variables).
network(score) = β + β1PC1 + β2PC2 + β3PC3 (3.1)
The network image is illustrated in Figure 3.9. It is characterized by increase FBB reten-
tion in the cortical regions relative to the deep white matter. It showed high retention
in the temporal cortex region, frontal cortex region, putamen, precuneus, anterior and
posterior cingulate regions.
FIGURE 3.12: Clinical classified Amyloid-positive or negative group re-
lated PC Network Image. colour bar indicates the level of amyloid accu-
mulation, the Yellow/red regions are high amyloid accumulation (FBB
retention) and the blue regions are no FBB retention
3.3.3 Network Image correlation with the cognitive parameters
The association of the PC network score with the CogZ was investigated, which showed
a highly significant group-by-cognition interaction, where the amyloid-positive group
showed a negative correlation with the global cognitive Z score ( r= 0.75, t = -2.21, p =
0.033, CI95:[-0.52 -(-0.023)]) (figure 3.13A) and also with MoCa score ( r= 0.75, t = -2.56,
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p = 0.014, CI95:[-0.09 -(-0.011)]) (figure 3.13B), No such correlation for the FBB(-) group
was found.
FIGURE 3.13: Network score group-by-cognition interaction with Global
cognitive Z Score (t = -2.21, p = 0.033) and MoCa Score (t = -2.56, p =
0.014)
3.4 Independent Component Analysis
In ICA, the components are not orthogonal and are not ranked according to the rele-
vance of the component. So, in order to understand the pattern of variance and the
pattern in our data set, we need to look at all the components separately. In this study,
25 components were acquired , from which 17 components showed an association with
the clinical classification of the individuals. However, none of the components were
able to provide any association with the cognitive parameters. Since, it was unable to
provide any association with the neuropsycological test scores, I didn’t look further
into the ICA.
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3.5 Bootstrapping
In order to test the reliability of our PC-Network, SUVR PET images were randomly
sampled with replacement, to form a resampled data set of the population of 50 PET
images. Bootstrapping was applied 5000 times and each time a new network image
was generated with the new resampled data. The 5000 network images were averaged
and an approximate standard deviation of the resampled population was obtained.
Using the approximate standards deviation and the mean image we acquired Z-scores
for each voxel. A threshold value of 1.96 was set to obtain regions which significantly
contribute to PD pathology.
The Z-score image (Figure 3.14) provided much more clarity and provides robustness
in the association between these regions shown in red in Figure 3.14 with amyloid de-
position in PD-MCI. It showed that most of the amyloid accumulation was observed
in the temporal cortical region, precuneus region and the anterior cingulate. There was
no significant uptake in the putamen or caudate nucleus.
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Chapter 4
Discussion
Patients with PD have an increased risk of advancing to dementia. Cognitive impair-
ment is now seen as a major feature of PD. It is most likely a result of a complex inter-
play of pathology including alpha synuclein pathology, AD pathology ( tau, β amyloid)
and neurotransmitter dysfunction (Silbert & Kaye, 2010). These pathologies may accel-
erate each other to worsen the state of the disease. In recent years, the role of β amyloid
has been a focus for research on cognitive impairment in PD.
Our study, showed that FBB-PET imaging allows invivo visualization of amyloid depo-
sition in PD. Specifically, 11 subjects (22%) from the PD-MCI group at baseline showed
AD-type neocortical FBB-binding, which may contribute to an increased risk of devel-
oping dementia. Our finding was slightly different than an earlier finding by Peder-
sen. et.al.; According to their study, 27% of PD-MCI cases exhibited amyloid positive
scans (Pedersen, Larsen, Tysnes, & Alves, 2013). However, a different group showed
only 15% of their population of 40 PD-MCI exhibited AD-type neocortical PiB binding
(Petroou, Bohnen, Muller, Albin, & Frey, 2012). On the other hand, our study was in
agreement with the previous studies, on the basis of the regions associated with AD-
type amyloid deposition in PD. These regions were neocortical, frontal and temporal
cortex, anterior and posterior cingulate, precuneus, caudate nucleus and thalamus as
seen in figure 3.14.
From our quantitative PET data analysis in section 3.2, we were able to show increased
uptake of FBB in a group clinically classified as amyloid-positive, relative to those clas-
sified as amyloid-negative (Table 3.2). A significant difference in the uptake of FBB
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between the two classes was observed in multiple regions: composite neocortical re-
gion, frontal cortical region, temporal cortical region, posterior cingulate, anterior cin-
gulate, putamen and precuneus. However, we found no significant difference in the
uptake of FBB between the two groups in the caudate nucleus and thalamus. The
finding of increased FBB in the putamen, but not the caudate is interesting. Goldstein
et.al. showed lower F-DOPA uptake in the putamen compared to the caudate nucleus
(Goldstein, Holmes, Sewell, & Kopin, 2009), indicating large deficit in the putamen.
The dopamine pathway appears to deteriorate earlier in the putamen in comparison
to the caudate nucleus. The increased FBB and decreased dopamine indicates that the
putamen is particularly hard hit in PD; showing the contribution of AD-pathology and
neurotransmitter deterioration "working together" in the progression of the disease.
Region of interest analysis and global analysis confirmed that there was a significant
group-by-cognition interaction, showing that the neocortical uptake of FBB was signifi-
cantly correlated with the global cognitive Z score only in the FBB(+) group (figure 3.3).
However, this relation did not exist in the amyloid-negative group. This suggests that
amyloid accumulation may contribute to cognitive impairment but only after a thresh-
old is reached. Or it could be that variation in low β-amyloid levels, i.e. sub-threshold,
have no effect on cognitive ability. However, as the presence of amyloid plaques begin
to accumulate, this could start to contribute to cognitive deterioration along with other
pathological processes. We observed a negative correlation between amyloid accumu-
lation and cognitive impairment, meaning with higher amyloid accumulation in the
neocortial region, worse global cognitive impairment was observed. This association
was also observed in previous studies, showing a higher PiB retention associated with
worse global cognitive impairment (Petroou et al., 2012) and (Gomperts et al., 2013).
Similar correlations between FBB uptake and global cognitive Z score were made in
the: anterior cingulate, posterior cingulate and precuneus. This shows the importance
of these region for cognition and the association of amyloid accumulation with cogni-
tive decline in PD-MCI.
We also showed significant association between amyloid accumulation and Parkin-
son’s disease dementia conversion score (probability of PD conversion to dementia
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within four years). This is a positive step towards showing the contribution of amyloid
accumulation to the development of future dementia in PD-MCI, indicating that amy-
loid deposition may be a contributing factor to the development of future dementia in
PD.
We used multivariate data analysis method (principal component analysis) to identify
the pattern of amyloid accumulation in PD that best separates the FBB(+) and FBB(-)
group. Prior to our study, only a few studies have used PCA to understand the distri-
bution of PiB in PD and AD (Campbell et al., 2013).
We analysed components that in total captured 66% of the variance within our data.
For this study, the principal components 1, 2, 3 ,4 and 5 collectively explained 68.9 %
of the variance in the data set. Each of the principal components encompassed a dif-
ferent pattern of amyloid accumulation. Principal components 1, 2 and 3 all showed
an association with the clinical classification of amyloid positivity. In order to under-
stand the PD-related pattern of amyloid accumulation, I employed linear combination
of principle components 1, 2, and 3 to derive a pattern of amyloid distribution that best
separated FBB(+) and FBB(-).
Principal component 1 showed an association with learning ability and acquiring new
information indicating that the pattern of FBB accumulation affected learning and mem-
ory. The pattern of uptake for principal component 1 was similar to the pattern of
uptake seen by Campbell et al. i.e. FBB retention in the cortical region (Campbell
et al., 2013). Furthermore, we also showed a positive correlation between principal
component 2 FBB uptake pattern and executive domain impairment for FBB(+) group.
Higher accumulation of amyloid in the temporal cortex, prefrontal cortex and anterior
and posterior cingulate was associated with the worsening of an individuals ability to
solve problems and plan for the future. This finding is consistent with the anatomy of
executive function, as the area of the brain that plays an important role in executive
function is the preforntal cortex (Katz, Zafonte, & Zasle, 2006). So an abnormality in
this region (e.g. excessive amyloid deposition) may result in executive dysfunction.
Principal component 3 and 5, driven from variation in white matter and FBB retention
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in the thalamus, respectively, showed no relation with the neuropsychological cogni-
tion test and other tests measured in our group. This is an interesting finding in that
the thalamus is an important structure for effective cognitive processing. ROI analy-
sis showed that the thalamus was relatively spared by amyloid deposition, suggesting
that structural (Melzer et al., 2012) and diffusion (Melzer et al., 2013) deficits under-
lying cognitive dysfunction are not influenced by amyloid pathology in the thalamus.
However, component 4 showed a very interesting relationship with the white matter
hyperintensity lesion volumes. A study conducted by Chao et.al, showed a similar
association in which individuals with WMH pathology were more vulnerable to the
effect of AD pathology and amyloid-β deposition in cortical regions (Chao et al., 2013).
β-amyloid is known to cause oxidative damage and results in the formation of free ra-
dials and damage to oligodendrocites. Furthermore, an initial elevation of amyloid-β
results in damage to the white matter which in turn causes increased level of β-amyloid
(Gordon, d Phillip Hsu, Roe, Morris, & Benzingera, 2015). Therefore, the extent of
white matter lesions could predict the level of amyloid accumulation and perhaps pro-
vide an indirect measure of β-amyloid deposition.
As mentioned earlier, a network indicating the distribution of increased amyloid ac-
cumulation was created. It showed the specific pattern of regional uptake in the brain
associated with amyloid accumulation. Prominent regions with amyloid accumula-
tions included the temporal cortical region, medial frontal cortical region, precuneus,
putamen, anterior cingulate and posterior cingulate. This finding is consistent with the
previous studies and also resembles an "AD like accumulation pattern". However, the
network showed that the hippocampus in our data was not included in the areas as-
sociated with high level of β-Amyloid (the blue region in figure 3.14). This shows that
amyloid accumulation in PD may not necessarily be the same as that expected in AD.
However, this was not directly compared, therefore, future studies directly compar-
ing amyloid accumulation in PD-MCI and AD-MCI would help to confirm our initial
observation.
The network score for the amyloid-positive group showed an association with the
global cognitive Z score and also the MoCa score (figure 3.13). However, it showed
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no association with the Parkinson’s disease dementia conversion score (PDDRS). It is
interesting to note that the network score was associated with the cognition Z score
but not with the PDDRS. This indicates that the cortical amyloid deposition may im-
pact current cognitive status, but may not provide information about future status.
However, PDDRS is a prediction and we would have to wait and see if any of the cur-
rent PD-MCI participant develop dementia over the course of the next 3 years. This
is exactly what this continuing study intend to do. PD-MCI participants will now be
followed to determine whether they do in fact develop dementia. Future work would
then investigate whether baseline FBB scans contribute to the prediction of dementia
development.
This study has some limitations which would be interesting to work on in the future.
Since the sample were only PD-MCI , we did not obtain data from participants across
the cognitive spectrum. Therefore, future research should look at comparing our results
from PD-MCI to controls (PD-N and PDD). Also, since in this study we found the "AD
like accumulation pattern" in some regions. It would be interesting to compare our
PD-MCI findings with the AD-MCI population.
In this study we employed standard uptake value ratio (SUVRs) as our tool to calculate
the radioactivity concentration for regions of interest. In future, it would be interesting
to acquire arterial blood sampling for these participants, along with SUVRs. Arterial
blood concentration is a measure which provides information of the concentration of
the radiotracer as function of time (Phelps, 2004). This is important, as it is the concen-
tration of radiotracer that feeds into various tissues (Phelps, 2004).
In the case of motion correction, we employed the second method (discussed in section
2.5.2), where we applied attenuation correction before motion correction. Even though,
we obtained good quality images for our analysis, it would be interesting to work on
the first method, where motion correction is employed before attenuation correction.
Motion correction prior to attenuation correction, has been shown to provide better
image quality in terms of visibility of possible amyloid deposition, size and contrast
of images. I looked at the radon transformation method as a reconstruction tool for
attenuated corrected sinogram, which reduced the image quality. However, I believe
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by employing the iterative reconstruction method (which is employed by the image
reconstruction in PET/CT scanner) we could potentially reconstruct images which will
provide us with better image quality. We were unable to look at the iterative recon-
struction method in this thesis as we did not have access to the specific software and
were unable to manually apply this reconstruction method due to time constraints.
However, even though we has some limitations to this study. This study have one huge
strength, which is the sample size of fifty PD-MCI participants. This sample size has
previously never been examined to study amyloid burden in PD-MCI using amyloid-
PET imaging.
Chapter 5
Summary
The aim of this thesis was to evaluate the use of FBB-PET imaging as a tool for invivo
visualisation of amyloid accumulation in PD-MCI. Another relative aim was to deter-
mine the association of amyloid accumulation with the cognitive decline and clinical
evaluation in PD-MCI. The reason for this study was to contribute to the ongoing longi-
tudinal study, in helping to predict which individuals with PD-MCI are at higher "risk"
of developing dementia in the near future.
We showed that FBB-PET imaging may be an extremely valuable tool for assessing
amyloid accumulation in PD. We found that around 22% of the PD-MCI in our study
population showed amyloid positivity, suggesting that individuals with PD-MCI may
have amyloid deposition. Using principal component analysis, I identified a pattern
(regions) of amyloid accumulation in the PD-MCI patient, which were similar to that
found in studies examining AD type amyloid deposition. These regions were: neo-
cortical, frontal and temporal cortex, precuneus, anterior and posterior cingulate, cau-
date nucleus and thalamus. Impairment in executive function, attention, learning and
memory appears to be associated with the accumulation of amyloid in the regions men-
tioned earlier.
Finally, this study was able to show that once amyloid plaque accumulation begins
in the cortical and subcortical regions described above, it could start to contribute to
cognitive deterioration in PD-MCI. Thus taking a positive step showing that amyloid
deposition may play an important role in PD and the development of future dementia.
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Appendix A
Matlab code for attenuation
correction and Image reconstruction
% CT based ATTENUATION CORRECTION for PET
% 9/07/2015 − Guneet Kaur
% Before using t h i s s c r i p t to r e c o n s t r c u t the at tenuated c o r r e c t e d
% PET image . 1 ) make sure t h a t the TOFNAC PET images are rea l igned
% and a sum image i s crea ted .
% 2) downsample the CT image in order to co−r e g i s t e r i t to the PET
% and MR image . 3 ) co−r e g i s t e r the CT image and PET summed Image using
% SPM co−r e g i s t e r batch .
% 4) make sure t h a t both the CT and PET summed image i s a l s o
% co−r e g i s t e r e d to the MR s t r u c t u r a l (down sampled image 256X256 )
%Load down sampled CT image to PET image
%Only works for 1 image at the moment .
[ i n p u t f i l e ] = spm_select ( 1 , ’ image ’ , ’ S e l e c t down sampled CT image ’ ) ;
CT_im = spm_vol ( i n p u t f i l e ) ;
% Load the PET image for teh same indiv idua l
input2 = spm_select ( 1 , ’ image ’ , ’ S e l e c t PET image ’ ) ;
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PET_im = spm_vol ( input2 ) ;
%Read the CT and PET image .
CT = spm_read_vols ( CT_im ) ;
PET = spm_read_vols ( PET_im ) ;
%% This s tep i s using the CT image only
% convert the HU value to l i n e a r a t t e n u a t i o n c o e f f i c i e n t (LAC) a t 511 keV
% use the standard l i n e a r c o e f f i c i e n t value for water and bone .
LAC = zeros ( s i z e (CT ) ) ;
i f CT<= 0
LAC = ( 0 . 0 9 6 . ∗ ( CT+ 1 0 0 0 ) ) . / 1 0 0 0 ;
e lse
LAC = ( 0 . 0 9 6 + (CT.∗ ( ( 0 . 1 8 4 . ∗ ( 0 . 1 7 2 −0 . 0 9 6 ) ) . / ( 1 0 0 0 .∗ ( 0 . 4 2 8 − 0 . 1 8 4 ) ) ) ) ) ;
end
LAC;
%%
% Eliminate the l i n e a r a t t e n u a t i o n values below 0 s i n c e i t s noise .
l a c _ z e r o= s i z e ( f ind (LAC< 0 ) , 1 ) ;
LAC(LAC<0) = 0 ;
% c r e a t e an image of the LAC MAP
[ pth , nam, ext ] = spm_f i l epar t s ( CT_im . fname ) ;
CT_im . fname = [ pth f i l e s e p nam ’_LAC ’ ext ] ;
CT_im . dt = [16 0 ] ;
spm_write_vol ( CT_im ,LAC)
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%% c r e a t i n g a sinogram of the Linear a t t e n u a t i o n map using the
%radon transform . Create 3D sinogram space
t h e t a = 0 : 1 7 9 ;
for s l i c e =1: s i z e (LAC, 3 )
lac_2d = LAC ( : , : , s l i c e ) ;
%d e f a u l t 0 :179
[R , xp ] = radon ( lac_2d , t h e t a ) ;
R_3d ( : , : , s l i c e ) = R ;
end
%V i s u a l i z e the sinogram across a l l s l i c e s .
f i g u r e ;
colormap gray
for s l i c e =1: s i z e (LAC, 3 )
imshow ( R_3d ( : , : , s l i c e ) , [ ] , ’ Xdata ’ , theta , ’ Ydata ’ , xp ,
’ I n i t i a l M a g n i f i c a t i o n ’ , ’ f i t ’ )
pause ( 0 . 3 )
end
%another way to display a s i n g l e s l i c e .
%imagesc ( theta , xp , R)
%% c a l c u l a t e the Attenuation c o r r e c t i o n f a c t o r and c r e a t e
% a ACF sinogram . Do c a l c u l a t e the ACF we c a l c u l a t e the
% exponent ia l of l i n e i n t e g r a l and f ind the r e c i p r o c a l .
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ACF = exp(−R_3d);% exponent ia l of the l i n e i n t e g r a l
a c f = 1./ACF;
% r e c i p r o c a l of the at tenuat ion , ’ Shepp−Logan ’ i s used for the
%a t t e n u a t i o n c o r r e c t i o n of the i n t e n s i t y of each voxel .
%Display ACF
f i g u r e ;
colormap gray
for s l i c e =1: s i z e (LAC, 3 )
imagesc ( theta , xp , a c f ( : , : , s l i c e ) )
pause ( 0 . 3 )
end
%Test out inverse radon
I = iradon (R , t h e t a ) ;
imagesc ( I ) ;
%%
% Inverse radon transform the acf−−to get the a c f image , j u s t to have a
% look , but not necessary . . .
%f i g u r e
%I2 = iradon ( acf , t h e t a ) ;
%imagesc ( I2 )
%f i g u r e ; h i s t ( a c f )
%f i g u r e ; h i s t (R)
%%
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for s l i c e =1: s i z e (LAC, 3 )
PET_2d = PET ( : , : , s l i c e ) ;
%d e f a u l t 0 :179
[ P , xr ] = radon ( PET_2d , t h e t a ) ;
pet_R_3d ( : , : , s l i c e ) = P ;
end
f i g u r e ;
for s l i c e =1: s i z e (LAC, 3 )
imagesc ( theta , xp , pet_R_3d ( : , : , s l i c e ) )
pause ( 0 . 3 )
end
%%
% mult iple the pet dinogram by the a c f c o e f f i c i e n t s to c r e a t e the
% a t t e n u a t i o n c o r r e c t e d PET sinogram
att_PET_sino = pet_R_3d . ∗ a c f ;
%%
% converts the sinogram i n o t an image
for s l i c e =1: s i z e (LAC, 3 )
imagesc ( theta , xr , at t_PET_sino ( : , : , s l i c e ) )
pause ( 0 . 3 )
end
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%Use the inverse Radon to convert back i n t o image space
for s l i c e = 1 : s i z e (LAC, 3 ) ;
acPET_im ( : , : , s l i c e ) = iradon ( att_PET_sino ( : , : , s l i c e ) , theta , ’ ram−lak ’ ) ;
a =iradon ( att_PET_sino ( : , : , s l i c e ) , t h e t a ) ;
end
%%
%acPET_im i s the 3D, motion−c o r r e c t e d ( done p r i o r to t h i s s c r i p t ) ,
%a t t e n t u a t i o n−c o r r e c t e d PET image .
[ pth , nam, ext ] = spm_f i l epar t s ( PET_im . fname ) ;
%Get the scan number
s1 = regexp (nam, ’\_ ’ , ’ s p l i t ’ ) ;
sub = char ( s1 ( 3 ) ) ;
PET_im . fname = [ pth f i l e s e p ’ ac_AB_PET_fft ’ sub ext ] ;
spm_write_vol ( PET_im , acPET_im )
Appendix B
Matlab code for Standard uptake
value ratio calculation
%This s c r i p t c a l c u l a t e s the standard uptake value r a t i o
%Only works for 3 images a t the moment .
[ i n p u t f i l e 1 s t s ]= spm_select ( 3 , ’ image ’ , ’ 1 s t PET , 2nd WM, 3rd cerebellum ’ )
vph1=spm_vol ( i n p u t f i l e 1 ( 1 , : ) ) ;
hot1=spm_read_vols ( vph1 ) ;
vph2=spm_vol ( i n p u t f i l e 1 ( 2 , : ) ) ;
hot2=spm_read_vols ( vph2 ) ;
vph3=spm_vol ( i n p u t f i l e 1 ( 3 , : ) ) ;
hot3=spm_read_vols ( vph3 ) ;
%Don ’ t inc lude NaNs in c a l c u l a t i o n of mena .
gm_cer=(~ isnan ( hot1 ) ) & ( hot3 >0) & ( hot2 > 0 . 2 ) ;
%Get mean PET value within region defined as
%c e r e b e l l a r WM , GM or whole brain .
avg_pet_gm=mean( hot1 ( gm_cer ) ) ;
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%Create SUVR by dividing by the avb_pet_wm value .
suvr_pet=hot1/avg_pet_gm ;
%∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗∗
%Write as image .
[ pth nam]= s pm_f i l e par t s ( vph1 . fname ) ;
s1=regexp (nam, ’\_ ’ , ’ s p l i t ’ ) ;
sn=char ( s1 ( 4 ) ) ;
vph1 . fname=[ pth f i l e s e p ’ sum_suvr_cerebellum_GM_ ’ sn ’ . n i i ’ ] ;
spm_write_vol ( vph1 , suvr_pet ) ;
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